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ABSTRACT 
Background Huntington’s disease (HD) is a fatal inherited neurodegenerative disease, caused by a 
CAG repeat expansion in HTT. Age at onset (AAO) has been used as a quantitative phenotype in 
genetic analysis looking for HD modifiers, but is hard to define and not always available.  Therefore 
here we aimed to generate a novel measure of disease progression, and identify genetic markers 
associated with this progression measure. 
Methods  We generated a progression score based on principal component analysis of prospectively 
acquired longitudinal changes in motor, behavioural, cognitive and imaging measures in the 
TRACK-HD cohort of HD gene mutation carriers (data collected 2008 – 2011).  We generated a 
parallel progression score using 1773 previously genotyped subjects from the REGISTRY study of 
HD mutation carriers (data collected 2003 – 2013). 216 subjects from TRACK-HD were genotyped.  
Association analyses was performed using GCTA, gene-wide analysis using MAGMA and meta-
analysis using METAL.  
Findings  Longitudinal motor, cognitive and imaging scores were correlated with each other in 
TRACK-HD subjects, justifying a single, cross-domain measure as a unified progression measure in 
both studies. The TRACK-HD and REGISTRY progression measures were correlated with each 
other (r=0·674), and with AAO (r=0·315, r=0.234 respectively). A meta-analysis of progression in 
TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1.12x10
-10
) on chromosome 
5 spanning 3 genes, MSH3, DHFR and MTRNR2L2. The lead SNP in TRACK-HD (rs557874766) is 
genome-wide significant in the meta-analysis (p=1.58x10
-8
), and encodes an amino acid change 
(Pro67Ala) in MSH3.  In TRACK-HD, each copy of the minor allele at this SNP is associated with a 
0.4 (95% CI=0.16,0.66) units per year reduction in the rate of change of the Unified Huntington’s 
Disease Rating Scale (UHDRS) Total Motor Score, and 0.12 (95% CI=0.06,0.18) units per year in 
3 
the rate of change of UHDRS Total Functional Capacity. The associations remained significant after 
adjusting for AAO. 
Interpretation  The multi-domain progression measure in TRACK-HD is associated with a 
functional variant that is genome-wide significant in a meta-analysis. The strong association in only 
216 subjects implies that the progression measure is a sensitive reflection of disease burden, that the 
effect size at this locus is large, or both. As knock out of Msh3 reduces somatic expansion in HD 
mouse models, this highlights somatic expansion as a potential pathogenic modulator, informing 
therapeutic development in this untreatable disease.  
Funding sources  The European Commission FP7 NeurOmics project; CHDI Foundation; the 
Medical Research Council UK, the Brain Research Trust, the Guarantors of Brain.
Research in context  
Evidence before this study 
Huntington’s disease (HD) is universally caused by a tract of 36 or more CAG in exon 1 of HTT. 
Genetic modifiers of age at motor onset have recently been identified in HD that highlight pathways, 
which if modulated in people, might delay disease onset.  Onset of disease is preceded by a long 
prodromal phase accompanied by substantial brain cell death and age at motor onset is difficult to 
assess accurately and is not available in disease free at risk subjects.  We searched all of PubMed up 
to Oct 31st 2016 for articles published in English containing “Huntington* disease” AND “genetic 
modifier” AND “onset” which identified 13 studies, then “Huntington* disease” AND “genetic 
modifier” AND “progression” which identified one review article.  Amongst the 13 studies of 
genetic modification of HD onset most were small candidate gene studies; these were superseded by 
the one large genome wide genetic modifiers of HD study which identified three genome-wide 
significant loci, and implicated DNA handling in HD disease modification 
4 
Added value of this study 
We examined the prospective data from TRACK-HD and developed a measure of disease 
progression that reflected correlated progression in the brain imaging, motor and cognitive symptom 
domains: there is substantial correlation among these variables. We used the disease progression 
measure as a quantitative variable in a genome-wide association study and in only 216 people from 
TRACK-HD detected a locus on chromosome 5 containing three significant genes, MTRNR2L2,  
MSH3 and  DHFR. The index variant encodes an amino acid change in MSH3. We replicated this 
finding by generating a parallel progression measure in the less intensively phenotyped REGISTRY 
study and detected a similar signal on chromosome 5, likely attributable to the same variants. A 
meta-analysis of the two studies strengthened the associations. There was some correlation between 
the progression measures and AAO of disease but this was not responsible for the association with 
disease progression. We also detected a signal on chromosome 15 in the REGISTRY study at the 
same locus as that previously associated with AAO. 
Implications of all the available evidence 
The progression measures used in this study can be generated in asymptomatic and symptomatic 
subjects using a subset of the clinically relevant parameters gathered in TRACK-HD.  We use these 
measures to identify genetic modifiers of disease progression in HD.  We saw a signal in only 216 
subjects, which replicates in a larger sample, becoming genome-wide significant, thus reducing the 
chance of it being a false positive.  This argues for the power of better phenotypic measures in 
genetic studies and implies that this locus has a large effect size on disease progression. The index 
associated genetic variant in TRACK-HD encodes a Pro67Ala change in MSH3, which implicates 
MSH3 as the associated gene on chromosome 5. Notably, altering levels of Msh3 in HD mice 
reduces somatic instability and crossing Msh3 null mice with HD mouse models prevents somatic 
instability of the HTT CAG repeat and reduces pathological phenotypes. Polymorphism in MSH3 has 
been linked to somatic instability in myotonic dystrophy type 1 patients. MSH3 is a non-essential 
5 
neuronally expressed member of the DNA mismatch repair pathway and these data reinforce its 
candidacy as a therapeutic target in HD and potentially in other neurodegenerative expanded repeat 
disorders. 
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INTRODUCTION 
Huntington’s disease (HD) is a autosomal dominant fatal neurodegenerative condition caused by a 
CAG repeat expansion in HTT (1).  It is a movement, cognitive and psychiatric disorder, but 
symptoms, age of disease onset (AAO) and disease progression vary (2).  AAO (1, 3) reflects the 
trajectory of disease pathology up to the point of motor onset.  However, the transition from 
premanifest to manifest HD is gradual (4, 5), making clinical definition challenging, furthermore 
psychiatric and cognitive changes may not be concurrent with motor onset (6).  Despite this 
imprecision in defining onset, the  inverse correlation of HTT CAG repeat length and age at motor 
onset accounts for 50-70% of the observed variance in onset (7). Part of the remaining difference in 
onset age was recently shown to be genetically encoded, identifying genes of the  DNA damage 
response as likely to modify onset of HD (8).   
The need for clinical trials close to disease onset has motivated a raft of observational studies (5, 9, 
10).  This provides the opportunity to investigate the relationship between onset and progression, 
whether they are influenced by the same biology, and permits the study of subjects before clinical 
onset.  
TRACK-HD represents the most deeply phenotyped cohort of premanifest and symptomatic disease 
with annual visits involving clinical, cognitive and motor testing alongside detailed brain imaging (5, 
6). We used TRACK-HD (5, 6) data to generate a novel unified Huntington’s disease progression 
measure for use in a genetic association analysis.  We developed a similar measure in subjects from 
the REGISTRY study to replicate our findings (9).   
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MATERIALS AND METHODS 
Study design and participants 
All experiments were performed in accordance with the Declaration of Helsinki and approved by the 
University College London (UCL)/UCL Hospitals Joint Research Ethics Committee; ethical 
approval for the REGISTRY analysis is outlined in (8). Peripheral blood samples were donated by 
genetically-confirmed HD gene carriers, and all subjects provided informed written consent. 
TRACK-HD was a prospective observational biomarker study collecting deep phenotypic data 
including imaging, quantitative motor and cognitive assessments on adult subjects with early HD, 
premanifest HD gene carriers and controls (5, 6). It provides annually collected high quality 
longitudinal prospective multivariate data over three years (2008-2011) with 243 subjects at baseline 
(6)  (Figure 1).  Demographic details of these individuals are shown in Supplementary 
Information.   
REGISTRY(9) was a multisite prospective observational study which collected phenotypic data  
between 2003 – 2013 on over 13,000 subjects, mostly manifest HD gene carriers.  The aim is for 
annual assessments +/- 3 months, though this is variable.  The core data include: age, CAG repeat 
length, UHDRS Total Motor Score (TMS) and Total Functional Capacity (TFC); some patients have 
further assessments such as a cognitive battery (9).  1835 adult subjects from REGISTRY were 
included in this study on the basis of available genotype data (8). We obtained: TMS, symbol digit 
modality (SDMT), verbal fluency, Stroop colour reading, word reading and interference measures, 
functional assessment score, and TFC.   
Procedures 
For both studies, atypical severity scores were derived with a combination of principal component 
analysis (PCA) and regression of the predictable effects of the primary gene HTT CAG repeat length. 
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Details differed however, due to differences in nature of the two data sets. In TRACK-HD, 24 
variables were used to stratify the cohort in terms of disease progression (Supplementary 
Information). They were divided a priori into 3 broad domains: (1) brain volume measures, (2) 
cognitive variables, and (3) quantitative-motor variables. For each variable the input for analysis was 
the subject’s random longitudinal slope from a mixed effects regression model with correlated 
random intercepts and slopes for each subject. This model regressed the observed values on clinical 
probability of onset statistic (CPO) derived from CAG repeat length and age, and its interaction with 
follow-up length. The subjects' random slope estimates thus provided a measure of atypical 
longitudinal change not predicted by age and CAG length. Principal Component Analyses (PCA) of 
the random slopes was then used to study the dimensionality of these age and CAG-length corrected 
longitudinal changes. Further methodological detail, including control for potential demographic 
confounders, is given in Supplementary Methods and a flow chart is given in Figure 1.
For REGISTRY, in contrast to TRACK-HD, follow-up length and frequency was variable and 
missing data were substantial, making longitudinal progression analysis problematic. We therefore 
examined cross-sectional status at last visit, using a single unified motor-cognitive dimension of 
severity.  We performed multiple imputation to fill in missing data, derived PCA severity scores and 
regressed off the predictive effect of age, CAG length, and gender on the PCA severity scores 
derived from this data to obtain the measure of atypical severity at the last visit. This gives a single 
point “severity” score based on how advanced a subject is compared with expectations based on their 
CAG repeat and age.  1773 subjects had adequate phenotypic data to score; further detail is given in 
Supplementary Methods and a flow chart is given in Figure 1. 
Statistical and genetic analysis 
Data analyses were performed using SAS/STAT 14·0 and 14·1 primarily via the MIXED, FACTOR 
and GML procedures (11).   We occasionally used a log or inverse transform of a measure, with the 
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goal of better approximate normality of the distribution and the avoidance of inappropriate influence 
of extreme scores. 
218 TRACK-HD study participants with complete serial phenotype data were genotyped on Illumina 
Omni2.5v1·1 arrays, and quality control performed as described in Supplementary Methods. 
Imputation was carried out using the 1000 Genomes phase 3 data as a reference (Supplementary 
Methods). This yielded 9·65 million biallelic markers of 216 individuals. Genotypes for the 
REGISTRY subjects were obtained from the GeM-HD Consortium (8), where details of their 
genotyping, quality control, curation and imputation are provided.  
Association analyses were performed with the mixed linear model (MLM) functions included in 
GCTA v1·26(12). Conditional analyses were carried out using the COJO procedure included in 
GCTA. Because of the relatively small sample sizes, analyses were restricted to SNPs with minor 
allele frequency >1%. A meta-analysis of the TRACK-HD and REGISTRY association results was 
performed using METAL(13).  To test whether the association signals in TRACK-HD and 
REGISTRY could have arisen from the same causal SNPs, and whether these also influenced 
expression co-localisation analysis was carried out using GWAS-pw v0·21 (14). Gene-wide p-values 
were calculated using MAGMA v1·05, a powerful alternative to SNP-based analyses which 
aggregates the association signal inside genes while taking linkage disequilibrium (LD)  between 
SNPs into account (15), using a window of 35kb upstream and 10kb downstream of genes (16). Such 
an analysis can increase power over single-SNP analysis when there are multiple causal SNPs in a 
gene, or when the causal SNP is not typed and its signal is partially captured by multiple typed SNPs 
in LD with it. To maximise comparability with the GeM GWAS, our primary pathway analyses used 
Setscreen (17), which sums the log p-values of all SNPs in a pathway, also correcting for LD 
between SNPs. 
All of the methods and analyses mentioned in this section are described in more detail in 
Supplementary Information.  
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RESULTS 
We performed individual PCA of each domain and found that first PC scores were highly correlated 
between the domains (P < 0·0001 in all cases, Supplementary Information.) No phenotypic 
subtypes of symptom clusters in motor, cognitive or imaging domains were observed; rather, 
longitudinal change in TRACK-HD not predictable by CAG-age was distributed on a correlated 
continuum (Figure 2). We therefore repeated PCA of the measures combined across all domains. 
The first PC of this combined analysis accounted for 23.4% of the joint variance, and was at least 
moderately correlated (r>0·4) with most of the variables that contributed heavily to each domain-
specific first PC (Supplementary Tables 3 and 4). The first psychiatric PC has notably lower 
correlation with motor and cognitive domains and CPO variables, so was excluded from our 
progression measures. 
The cross-domain first principal component was used as a unified Huntington’s disease progression 
measure in the TRACK-HD cohort (Figure 1 and 2B). To confirm that our progression measure 
correlated with commonly recognised measures of Huntington’s disease severity not included in the 
progression analysis, we examined the residual change relationships between the progression score 
and UHDRS TMS change and TFC change after controlling for the CPO. We found a correlation of 
r=0·448 (p<0·0001) for the residual motor slope and r=-0·421 (p<0·0001) for the residual TFC 
slope.  One unit increase in unified Huntington’s disease progression measure corresponded to an 
increase of 0·71 (95% CI=0.34,1.08)  units per year in the rate of change of TMS, and an increase of 
approximately 0·2 (95% CI=0.12,0.30) units per year in the rate of change of TFC. The 15 fastest 
progressing subjects in TRACK-HD showed a mean annual rate of decline in the UHDRS TMS of 
2·52 more points per year than would be expected (Standard deviation =2.47, Standard Error of 
Mean =0.64); the 15 slowest progressing subjects had an annual TMS decline of 0·45 points less per 
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year than predicted by age and CAG length (Standard deviation =1.85, Standard Error of the Mean 
=0.48). 
Huntington’s disease subjects in the early stages of the disease were significantly faster progressors 
on the unified HD progression measure than those still in the premanifest phase (p < 0·0001).  
Amongst the 96 subjects who had experienced onset, the rater AAO showed the expected relation 
with predicted AAO based on CAG length (Supplementary Information), and earlier than 
predicted AAO was correlated with faster progression on our unified HD progression measure 
(r=0·315; p = 0·002). 
The unified HD progression measure developed in TRACK-HD could not be transferred directly to 
REGISTRY subjects with more limited data. Individual clinical measures in REGISTRY showed 
correlations across the motor, cognitive, and functional domains, consistent with our finding in 
TRACK-HD (Supplementary Information). PC1 accounted for 75·6% of the variance in severity; 
no other principal components explained any substantial amount of the common variance within the 
measures used (Supplementary Information). Therefore this first principal component was chosen 
as a measure of severity in the REGISTRY cohort (Figure 2C). Higher values of this measure mean 
greater severity than expected at a given time: we infer that this is the result of faster progression 
(Figure 2A) and we used this as the unified Registry progression measure. The unified REGISTRY 
progression measure and earlier than predicted AAO were modestly, but significantly, correlated (r = 
0·2338; p<0·0001) (Supplementary Information).  Atypically rapidly or slowly progressing 
subjects tend to become more atypical over time: correlation between time since disease onset and 
REGISTRY progression (-0·3074; p<0·0001) is greater than that between AAO and REGISTRY 
progression. 
In TRACK-HD, the last-visit severity scores had a correlation of 0·674 with the previously 
calculated longitudinal unified progression measure, indicating that our progression measures for 
TRACK-HD and REGISTRY reflected strongly, although not perfectly, related elements of clinical 
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phenotype. Further support for this conclusion was given by the correlation of 0·631 between the 
TRACK-HD and REGISTRY progression measures in the 14 subjects present in both studies. 
We then performed a genome-wide association analysis using the unified TRACK-HD progression 
measure as a quantitative trait, which yielded a significantly associated locus on chromosome 5 
spanning DHFR, MSH3 and MTRNR2L2.  The index SNP rs557874766 is a coding missense variant 
in MSH3 (p =5·8x10
-8
; G=0·2179/1091 (1000 Genomes); Figure 3A and D and Supplementary 
Information). Analyses conditioning on this SNP failed to show evidence for a second independent 
signal in this region in TRACK-HD (Supplementary Information). The genes in this locus were 
the only ones to reach genome-wide genic significance ((15, 18) (MTRNR2L2 p=2·15x10
-9
; MSH3
p=2·94x10
-8
; DHFR p=8·37x10
-7
, http://hdresearch.ucl.ac.uk/data-resources/ ).  
Performing a genome-wide association analysis in REGISTRY using the unified progression 
measure replicated the signal identified in TRACK-HD (lead SNP rs420522, p = 1·39 x 10
-5
) on a 
narrower locus (chr5:79902336-79950781), but still tagging the same three genes (Figure 3B and 
D). No genes reach genome-wide significance, though there is evidence of association 
(http://hdresearch.ucl.ac.uk/data-resources/) at DHFR (p=8·45x10
-4
), MSH3 (p=9·36x10
-4
), and 
MTRNR2L2 (p=1·20x10
-3
). 
The meta-analysis of TRACK-HD and REGISTRY strengthened the signal of both individual SNPs 
in this region, encompassing the first three exons of MSH3 along with DHFR and MTRNR2L2
(Figure 4C and D, Supplementary Information), and also genic associations over MSH3, DHFR, 
and MTRNR2L2 (http://hdresearch.ucl.ac.uk/data-resources/). The most significant SNP in the 
meta-analysis is rs1232027, which is genome-wide significant (p=1.12x10
-10
), with the p-value of 
rs557874766 being 1.58x10
-8
. No other regions attained genome-wide significance 
(http://hdresearch.ucl.ac.uk/data-resources/). Rs557874766 is nominally significant in 
REGISTRY (p=0.010), with a direction of effect consistent with that in TRACK-HD. Analyses 
conditional on rs1232027 largely remove the association in this region (Supplementary 
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Information), suggesting that there is only one signal. Conditioning on rs557874766 has a similar 
effect (Supplementary Information), so this SNP remains a plausible causal variant.  
As suggested by the meta-analysis, co-localisation analyses between TRACK-HD and REGISTRY 
showed this locus was likely influenced by the same SNPs in both studies (posterior probability 
74.33%), although conditioning REGISTRY on rs55787466 did not remove the association signal 
entirely (Supplementary Information). Co-localisation analyses with the GTeX expression data 
(19) showed strong evidence (posterior probability 96-99%) that SNPs influencing progression in 
TRACK-HD were also eQTLs for DHFR in brain and peripheral tissues (Supplementary 
Information). Conversely, there was strong evidence (posterior probability=97·8%) that progression 
SNPs in REGISTRY were eQTLs for MSH3 in blood and fibroblasts (Supplementary 
Information). Despite the lack of co-localisation between the TRACK GWAS and MSH3 
expression signal, several of the most significant GWAS SNPs were associated with decreased 
MSH3 expression and slower progression (Supplementary Information). Thus, the signal on 
chromosome 5 could be due to the coding change in MSH3, or to expression changes in MSH3, 
DHFR or both, and both effects may operate in disease. 
The second most significant association region in REGISTRY (Supplementary Information) tags a 
locus on chromosome 15 which has been previously associated to HD AAO (8). Five genes were 
highlighted, two of which reached genome-wide genic significance (MTMR10 p=2·51x10
-7
; FAN1
p=2·35x10
-6
, http://hdresearch.ucl.ac.uk/data-resources/).  Notably, MLH1 on chr3 contains SNPs 
approaching genome-wide significance (p = 2.2 x 10
-7
) in GeM-HD (8), and also shows association 
in the REGISTRY progression gene-wide analysis (p = 3·97x10
-4
).  
As noted earlier, both progression measures are correlated with AAO. Thus, to test whether there is 
an association with progression independent of AAO, we repeated the REGISTRY progression 
GWAS conditioning for the AAO measure previously associated with this locus in GeM in the 
individuals (N=1,314) for whom we had measures of both progression and AAO. Both MTMR10 
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(p=1·33x10
-5
) and FAN1 (p=1·68x10
-4
) remained significant (http://hdresearch.ucl.ac.uk/data-
resources/).  Furthermore, the most significant SNP (rs10611148, p=2·84x10
-7
) was still significant 
after conditioning on AAO (p=2·40x10
-5
). Notably, the genic associations at the MSH3 locus in the 
TRACK-HD sample also remain significant after correcting for AAO 
(http://hdresearch.ucl.ac.uk/data-resources/), as does the association with rs557874766 
(p=6·30x10
-6
). A similar pattern is observed at the MSH3 locus in the meta-analysis. Thus, the 
associations reported here are mainly due to disease progression, rather than AAO.   
Gene set analysis of the 14 pathways highlighted by the GeM-HD paper (8) show that the four most 
significant pathways in the TRACK-HD progression GWAS are related to mismatch repair, and all 
show significant enrichment of signal in REGISTRY (Table 1). This enrichment is strengthened in 
the meta-analysis (Table 1). Notably, the top two pathways in TRACK-HD are also significant in the 
MAGMA competitive gene-set analysis (GO:32300 p=0·010, KEGG:3430 p=0·00697). MSH3
(2.94x10
-8
) and POLD2 (7·21x10
-4
) show association in TRACK, with MSH3 (9·52x10
-4
) and MLH1
(3·97x10
-4
) showing association in REGISTRY (Supplementary Information). These findings are 
supported by analysis of DNA damage response pathways derived from Pearl et al. (20) (Figure 4A, 
Supplementary Information) where two mismatch repair pathways are significantly associated 
with the unified TRACK-HD progression measure after correction for multiple testing of pathways. 
Again, the meta-analysis strengthens the enrichment (Figure 4B, Supplementary Information).  
Genes from the two significant pathways in TRACK-HD are shown in the Supplementary 
Information, with the significant genes being very similar to those from the GeM pathways 
(Supplementary Information).  A complete list of genes in the Pearl et al. (20) pathways is given in 
http://hdresearch.ucl.ac.uk/data-resources/.
DISCUSSION  
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The evidence from our study suggests that MSH3 is likely to be a modifier of disease progression in 
Huntington’s disease. We undertook an unbiased genetic screen using a novel disease progression 
measure in the TRACK-HD study, and identified a significant locus on chromosome 5, which 
encompasses three genes: MTRNR2L2, MSH3 and DHFR. This locus replicated in an independent 
group of subjects from the European HD REGISTRY study using a parallel disease progression 
measure, and was genome-wide significant in a meta-analysis of the two studies. The lead SNP in 
TRACK-HD, rs557874766, is a coding variant in MSH3; it is classed of moderate impact, making it 
genome-wide significant given its annotation (21). This SNP becomes clearly genome-wide 
significant at the more widely used threshold of p=5x10
-8
 in a meta-analysis of TRACK-HD and 
REGISTRY. Furthermore, eQTL analyses show association of lower MSH3 expression with slower 
disease progression.   
Genetic modifiers of disease in people highlight pathways for therapeutic development; any pathway 
containing genetic variation that ameliorates or exacerbates disease forms a pre-validated relevant 
target. However, while the classical case-control design in complex disease has yielded multiple 
genetic associations highlighting relevant biology for novel treatment design (22), studies of 
potential genetic modifiers in genetically simple Mendelian diseases have been difficult to conduct. 
The diseases are rare and show gene and locus heterogeneity, thus finding genuine modifying 
associations in such a noisy background is inherently difficult.  However, variants that modify 
disease in the context of a Mendelian causative gene may not be under negative selection pressure in 
the general population.  Recent successful identifications of modifiers have been made in specific 
genetic subtypes of disease (23) or in relatively large samples with consistent clinical data (8, 24).    
One way to increase the power of genetic studies is to obtain a more accurate measure of phenotype. 
Prospective multivariate longitudinal measures such as those collected in TRACK-HD are ideal (25). 
Our analysis of Huntington’s disease progression showed that motor, cognitive and brain imaging 
variables typically progress in parallel and that patterns of loss are not sufficiently distinct to be 
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considered sub-phenotypes for genetic analysis. As psychiatric symptoms showed a different 
trajectory, we developed a single progression measure excluding the psychiatric data (Figure 2A 
and B). AAO was correlated with the unified progression measure but did not explain the genetic 
associations observed with progression. Thus, progression seems to be measuring a different aspect 
of disease to AAO, or a similar aspect of disease, but with greater precision. The data available in 
REGISTRY are less comprehensive; therefore we used a different approach by comparing cross-
sectional severity at the most recent visit with that expected based on age and CAG. The unified 
progression measures in TRACK-HD and REGISTRY are correlated and again, the genetic 
associations in REGISTRY are not completely driven by AAO, demonstrating the utility of 
retrospective composite progression scores in genetic analysis.  Prognostic indices for motor onset 
have been developed (26), and the development of progression scores for prospective use, for 
example to empower drug trials by stratifying patients by predicted rate of progression warrants 
further attention.  
However, our study has a number of limitations.  TRACK-HD has the same standardised detailed 
phenotypic information on nearly all participants, but in only 243 HD gene mutation carrying 
subjects.  The REGISTRY study is much larger but the phenotypic data are less complete 
(Supplementary Information), often not collected at regular intervals and not on everyone in the 
study, and in multiple centres which will inevitably lead to intrinsic variation. Nevertheless, the 
progression measures show the expected relationship with change in TMS and TFC in both TRACK-
HD and REGISTRY indicating their clinical relevance.  However, future development of the 
progression statistic and confirmation of the genetic association in subjects from ongoing large 
studies such as ENROLL (27), with data collected more systematically than in REGISTRY but in 
less detail than TRACK-HD, would be ideal. 
The genetic locus identified by the unified TRACK-HD progression measure association includes 
three genes, but MSH3 is the likeliest candidate. Firstly, the lead SNP is a coding variant in exon 1 of 
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MSH3, MSH3 Pro67Ala, with the potential to affect function (SNiPA(28) accessed 10/11/2016). 
Clinically, each copy of the minor allele (G) at this SNP corresponds to a decrease of approximately 
0.4 (95% CI=0.16,0.66) units per year in the rate of change of TMS, and a reduction of 
approximately 0.12 (95% CI=0.06,0.18) units per year in the rate of change of TFC (see 
Supplementary Information). Secondly, MSH3 has been extensively implicated in the pathogenesis 
of HD in both mouse and cell studies, though this is the first human study to link MSH3 to HD.  
MSH3 is a neuronally expressed member of a family of DNA mismatch repair proteins (29); it forms 
a heteromeric complex with MSH2 to form MutSβ, which recognises insertion-deletion loops of up 
to 13 nucleotides (30) (Figure 4D). There is, however, a high level of interconnectedness between 
pathways involved in the DNA damage response, and MutSβ is implicated in other processes (20). 
Changes in CAG repeat size occur in terminally differentiated neurons in several HD mouse models 
and in human patient striatum, the brain area most affected in HD, and notably, somatic expansion of 
the CAG repeat in HD patient brain predicts onset (31).  Msh3 is required for both somatic expansion 
of HTT CAG repeats and for enhancing an early disease phenotype in mouse striatum (32), Msh3 
expression level is associated with repeat instability in mouse brain, (whereas DHFR is not) (30) and 
expansion of CAG and CTG repeats is prevented by msh3Δ in Saccharomyces cerevisiae (33).  This 
gives a plausible mechanism through which variation in MSH3 could operate in HD (Figure 4C and 
D).  In patients with myotonic dystrophy type 1 (DM), somatic instability of the CTG repeat (CAG 
on the non-coding strand), is associated with age of onset and an MSH3 variant was recently 
associated with somatic instability in blood DNA of patients (34). Variants in DNA repair pathways 
including those in MSH3 contribute to age of onset modification of multiple CAG repeat expansion 
diseases (35) implicating the CAG repeat itself as the source of modification in these diseases.  
This is the first study to use a measure of progression to look for modifiers of a neurodegenerative 
Mendelian disorder.  We detected association with a coding variant on chromosome 5, reaching 
genome-wide significance given its annotation (21) in just 216 subjects, which replicated in a larger 
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independent sample and strengthened on meta-analysis. This indicates that either our progression 
measure developed in TRACK-HD is an excellent reflection of disease pathophysiological 
progression or that this is a locus with a very large effect size, or, most likely, both. While there are 
three genes at the locus, the most significant variant gives a coding change in MSH3, which together 
with the prior biological evidence makes it the most likely candidate.  Somatic expansion of the 
CAG repeat through alterations in MSH3 is a plausible mechanism for pathogenesis in HD which can 
be followed up in functional experiments in HD models. These data provide additional support for 
the therapeutic targeting of Huntingtin and the stability of its CAG repeat.  Loss of or variation in 
mismatch repair complexes can cause malignancy and thus they are not regarded as ideal drug 
targets, but MSH3 is not essential as it can tolerate loss of function variation (36) and could provide 
a therapeutic target in HD. We note that if it does operate to alter repeat expansion it may also be a 
drug target in other repeat expansion disorders. 
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Figure & Table legends 
Figure 1: Study Design.  After establishing that brain imaging, quantitative motor and cognitive 
variables are correlated and follow a similar trajectory, we scored the TRACK-HD subjects using 
principal component 1 as a Unified progression measure, and used this measure to look for genome-
wide associations with HD progression. We replicated our findings in the EHDN Registry subjects 
by looking at how far their disease had progressed compared with expectations based on CAG/Age, 
and used this progression measure to look for genome-wide associations in REGISTRY. 1835 
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Registry subjects had genotype data (8). UHDRS TMS: Unified Huntington’s Disease Rating Scale 
Total Motor Score. SDMT: symbol digit modality test. TFC: Total Functional Capacity.   
Figure 2: Assessing progression in Huntington’s disease (A) Graphical illustration of the trajectory 
of HD symptoms and signs over time, annotated to show what time period the different measures of 
onset and progression discussed in this paper cover. The TRACK-HD progression score uses 
longitudinal data over 3 years. Given limited longitudinal data in REGISTRY, cross-sectional 
severity at last visit compared to predicted severity was used as a proxy for progression. Age at onset 
occurs when a subject has unequivocal motor signs of Huntington’s disease. (B) Distribution of 
progression measure in 218 members of TRACK-HD cohort. (C) Distribution of atypical severity 
(compared to predicted severity at final visit) in in 1835 members of the REGISTRY cohort. The 
curves in (B) and (C) are the normal distribution approximations of the severity score distributions.
Figure 3: Genome-wide Association Analysis of Progression Score. Green line in A-C: 5x10
-8
. (A) 
Manhattan plot of TRACK-HD GWA analysis yielding a locus on chromosome 5. Significance of 
SNPs (y axis) is plotted against genomic location (x axis). (B) Manhattan plot of REGISTRY GWA 
analysis showing suggestive trails on chromosome 15 in the same area as the GeM GWAS 
significant locus (8), and chromosome 5 in the same area as the TRACK progression GWAS. (C)  
Manhattan plot of Meta-analysis of TRACK and REGISTRY progression analysis.  (D) Locus zoom 
plot of the TRACK-HD (top), REGISTRY (middle) and meta-analysis (bottom) data showing the 
structure of linkage disequilibrium (LD) and –log10(p-value)  of the significant locus on 
chromosome. The top image shows the chromosome; the red square shows the region which is 
zoomed in on in the other panels. The colours of the circles are based on r
2
 with the lead SNP in 
TRACK-HD as shown in the bottom of the plot; intensity of colour reflects multiple overlying SNPs. 
Dashed lines: 5x10
-8
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Figure 4: Significant genes are functionally linked and may cause somatic expansion of the HTT 
CAG repeat tract.  STRING diagram showing all proteins from the Pearl et al (20) dataset with gene-
wide p-values for association with Huntington’s disease progression < 0.02 in A: the TRACK-HD 
dataset and B, the meta-analysis of TRACK-HD and REGISTRY 
(http://hdresearch.ucl.ac.uk/data-resources/).  Genes with p<0.02 coloured; 10 further interactors 
in grey, confidence of interaction is shown in the ‘Edge confidence’ box, homo sapiens protein data 
used: http://string-db.org/cgi/ accessed October 2016 and January 2017 (37).  C Schematic diagram 
showing how DNA mismatch repair proteins may be involved in somatic expansion of the CAG 
tract. Proteins with p<0.01 in the meta-analysed progression GWAS are coloured red. (i) The CAG 
repeat DNA is partly unwound by lesions,  constraints of the CAG tract structure (middle image) or 
by transcription. (ii) This unwound DNA is recognised by MutSbeta (MSH2/MSH3) which recruits 
the endonuclease MutLalpha (PMS2/MLH1) and cleaves the DNA.  (iii) Repair of the strand break 
leads to expansion of the CAG repeat. In neurones of the striatum somatic expansion is an ongoing 
process that occurs throughout life and variants in MSH3 may promote or inhibit repeat recognition, 
binding or repair. D Potential link between degree of somatic expansion over a patient’s lifespan and 
rate of Huntington’s disease progression.  
Table 1: Setscreen enrichment p-values for the 14 pathways highlighted in GeM-HD (8). 
The GO and KEGG terms in the first column refer to pathways of biologically related genes in the 
Gene Ontology Consortium(1) and Kyoto Encyclopedia of Genes and Genomes (2) databases 
respectively. The p-values in columns 2 – 4 refer to the association between the pathway indicated 
and rate of progression described in this paper (TRACK- TRACK-HD study; REGISTRY- 
REGISTRY study; META- meta-analysis).  P(GeM) refers to the association between the indicated 
pathway and age at motor onset in the GeM-HD study (8).  
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Pathway p(TRACK) p(REGISTRY) P(META) p(GeM) Description
GO:   32300 3·46E-09 8·34E-04 1.14E-11 3·82E-05 mismatch repair complex                                    
KEGG    3430 2·79E-07 4·80E-02 1.34E-16 6·65E-06 mismatch repair (KEGG)
GO:   30983 6·66E-07 4·20E-04 3.17E-11 7·43E-06 mismatched DNA binding                                  
GO:    6298 3·53E-06 4·59E-02 6.54E-09 3·25E-06 mismatch repair                                                   
GO:   32407 1·82E-02 1·10E-01 6.40E-04 5·74E-05 MutSalpha complex binding                               
GO:   32389 2·25E-02 4·69E-02 5.23E-04 1·66E-05 MutLalpha complex                                            
GO:   33683 8·01E-02 5·87E-04 6.74E-03 1·69E-06 nucleotide-excision repair, DNA incision          
GO:   90141 3·32E-01 5·93E-02 7.87E-01 2·30E-06
positive regulation of mitochondrial 
fission                                                                  
GO: 1900063 4·10E-01 7·29E-01 6.93E-01 8·39E-05 regulation of peroxisome organization               
GO:   90200 4·58E-01 5·44E-01 5.28E-01 8·89E-08
positive regulation of release of 
cytochrome c from mitochondria                        
GO:   90140 5·39E-01 3·32E-01 8.10E-01 1·57E-05 regulation of mitochondrial fission                     
GO:   10822 6·21E-01 6·28E-01 8.53E-01 7·63E-05
positive regulation of mitochondrion 
organization                                                         
GO:    4748 9·64E-01 6·97E-01 9.79E-01 2·66E-05
ribonucleoside-diphosphate reductase 
activity, thioredoxin disulfide as acceptor          
GO:   16728 9·64E-01 6·97E-01 9.79E-01 2·66E-05
oxidoreductase activity, acting on CH or 
CH2 groups, disulfide as acceptor                      
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Table 1: Setscreen enrichment p-values for the 14 pathways highlighted in GeM-HD (8). The GO and 
KEGG terms in the first column refer to pathways of biologically related genes in the Gene Ontology 
Consortium(1) and Kyoto Encyclopedia of Genes and Genomes (2) databases respectively. The p-values in 
columns 2 – 4 refer to the association between the pathway indicated and rate of progression described in this 
paper (TRACK- TRACK-HD study; REGISTRY- REGISTRY study; META- meta-analysis).  P(GeM) refers 
to the association between the indicated pathway and age at motor onset in the GeM-HD study (8).  
Pathway p(TRACK) p(REGISTRY) P(META) p(GeM) Description
GO:   32300 3·46E-09 8·34E-04 1.14E-11 3·82E-05 mismatch repair complex                                    
KEGG    3430 2·79E-07 4·80E-02 1.34E-16 6·65E-06 KEGG_MISMATCH_REPAIR                          
GO:   30983 6·66E-07 4·20E-04 3.17E-11 7·43E-06 mismatched DNA binding                                  
GO:    6298 3·53E-06 4·59E-02 6.54E-09 3·25E-06 mismatch repair                                                   
GO:   32407 1·82E-02 1·10E-01 6.40E-04 5·74E-05 MutSalpha complex binding                               
GO:   32389 2·25E-02 4·69E-02 5.23E-04 1·66E-05 MutLalpha complex                                            
GO:   33683 8·01E-02 5·87E-04 6.74E-03 1·69E-06 nucleotide-excision repair, DNA incision           
GO:   90141 3·32E-01 5·93E-02 7.87E-01 2·30E-06
positive regulation of mitochondrial 
fission                                                                  
GO: 1900063 4·10E-01 7·29E-01 6.93E-01 8·39E-05 regulation of peroxisome organization               
GO:   90200 4·58E-01 5·44E-01 5.28E-01 8·89E-08
positive regulation of release of 
cytochrome c from mitochondria                        
GO:   90140 5·39E-01 3·32E-01 8.10E-01 1·57E-05 regulation of mitochondrial fission                     
GO:   10822 6·21E-01 6·28E-01 8.53E-01 7·63E-05
positive regulation of mitochondrion 
organization                                                         
GO:    4748 9·64E-01 6·97E-01 9.79E-01 2·66E-05
ribonucleoside-diphosphate reductase 
activity, thioredoxin disulfide as acceptor          
GO:   16728 9·64E-01 6·97E-01 9.79E-01 2·66E-05
oxidoreductase activity, acting on CH or 
CH2 groups, disulfide as acceptor                      
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Methods
Defining progression in TRACK-HD
Among the wide variety of potential cognitive and quantitative-motor variables, we analysed a subset of
those that were previously used in a 36-month predefined primary analysis(1). A small number of
quantitative-motor variables that were substantively redundant were eliminated and those with more
tractable metric properties were chosen (Supplementary Table 2).
For the Track HD study, 10 subjects were excluded because they had no follow-up data. 15 other subjects
were excluded because of missing brain MRI data there was no missing data for the other variables used in
the analysis.
Our models controlled for study site, gender, education, and their interactions with follow-up time,
consistent with the models used in the TRACK-HD standard analyses which are described elsewhere(1-4).
The dominance of the first principal component is shown in the Scree plot in Supplementary Figure 9.
Progression analysis in REGISTRY
We used a square-root transform of TMS to improve approximate multivariate normality of the data.
Missing data were considerable as documented Supplementary Table 15.
To deal with the missing data for clinical items, multiple imputation with 25 imputations was performed.
Age, gender, and CAG expansion length were auxiliary variables for the imputations. Proper methods to
account for imputation variation were used for all statistical inferences. Final parameter estimates and
statistical significance were estimated by Rubin's method(5). We performed the above using the MI and
MIANALYZE procedures of SAS/STAT 13.1(6).
In order to generate atypical severity scores, we needed to undertake three sequential procedures: (i)
Multiple imputation of missing data (ii) Principal Component Analysis (PCA) and severity scoring of the
combined imputed data replications (iii) Regression of the predictive effect of age, CAG length, and gender
on the PCA-derived severity scores so that we are left with a measure of atypical (or unexplained)
severity. The steps were taken in the order above; given that these steps could be done in different orders we
also confirmed that there were only minimal differences due to the order (data not shown). We also noted
some evidence of study site effects in the eventual regressions. Thus we used a random effect for site in
models adjusting for age and CAG. Atypical severity was defined as the residual between each subject's
observed and marginal predicted value. The dominance of the first principal component is shown in
Supplementary Figure 10.
The final averaged multiple imputation model used a 2 degree of freedom restricted cubic spline(7) of
cumulative probability of onset (CPO), plus main effects of gender and CAG length and a random effect for
site. Marginal effects from this model, which represent the estimated effects after accounting for site
fluctuations, were used for all predictions. The knot placement for the clinical probability of onset spline
was defined a priori using a conventional standard at the 10
th
, 50
th
, and 90
th
percentiles of its observed
distribution. The corresponding values were (0.131, 0.395, 0.885). Atypical severity was defined as the
residual between each subject's observed and marginal predicted value. Final parameter estimates, along
with estimates of statistical significance adjusted for the multiple imputation procedure are shown in the
Supplementary Table 16.
We inspected the potential biasing influence of the CAG repeats, by classifying the individual in short (CAG
< 41) and long (CAG > 55) repeats. We found an overrepresentation of people with larger atypical severity
scores among those with short CAG, which implies that those with a small number of repeats are more
likely to be in the study if atypically severely affected. This is likely to be due to the disease only being
partially penetrant in those with short CAG repeats, resulting in bias (8). This prompted us to exclude
subjects with short CAG from the creation of the severity scores, while retaining those with long CAG.
However, we confirmed that the age-CAG severity function predicted using CAG > 41 gave sensible
estimates for both the short and long ranges, enabling even those subjects with short CAG to be used in the
final analysis (Supplementary Figure 11).
Comparing TRACK-HD and REGISTRY progression measures
There are four common measures between TRACK-HD and REGISTRY: TMS, symbol digit score, Stroop
word reading score and TFC. We took the first principal component score from an analysis of these four
measures at the last TRACK-HD visit: this accounted for 79.4% of the variance in the PCA and correlated
approximately equally with each of the four observed variables (Supplementary Table 21). To calculate
the measure of severity unaccounted for by age and CAG length in TRACK, we regressed these principal
component scores on the same predictors used for the unified REGISTRY progression measure, to give
TRACK-HD severity scores.
As explained in the manuscript page 13, within the TRACK-HD data, the last-visit severity scores had a
Pearson correlation of 0·674 with the previously calculated longitudinal progression measure. It can be
shown that the predicted values obtained from the TRACK-HD and REGISTRY formulas are nearly linear,
hence that Pearson correlation should be an adequate descriptive statistic for the relationship
(Supplementary Figure 12).
Genotyping and quality control
DNA was obtained from blood samples of the 218 TRACK-HD study participants who had complete serial
phenotype data, using standard methods (2). Genotyping was performed in Illumina Omni2.5 v1.1 arrays at
UCL Genomics, in accordance with the Infinium LCG Assay (15023141_A, June 2010) protocol (Illumina
Inc, San Diego, USA). Standard QC procedures (9) were performed using PLINK v1.9 (10), including
controlling for coverage and call rates (5% of missing data allowed per SNP and individual), inbreeding (F <
0.2 required) and Hardy-Weinberg equilibrium (SNPs with p < 10
-6
in an exact test were removed). With
these criteria, and after removing one individual of a twin pair, a total of 216 gene positive TRACK-HD
subjects were left in the sample, genotyped for 2.34 million genome-wide markers (Figure 1).
Identity-by-descent analysis showed 9 pairs of individuals with a relatedness coefficient (ߨො) higher than
0.15, which included 6 putative first degree relatives, 2 putative second degree relatives and 1 putative pair
of third degree relatives. Additionally, an ADMIXTURE analysis with a subset of the 1000 Genomes (11)
populations revealed 6 individuals with more than 25% of non-European ancestry. All these individuals
were retained in the TRACK-HD sample, as their relatedness and admixture can be accommodated well by
using association methods based on mixed linear models (12, 13).
TRACK-HD was imputed in the Cardiff University high-performance computing cluster RAVEN(14), using
the SHAPEIT/IMPUTE2 algorithms(15, 16) and a standardised pipeline(17). The 1000 Genomes phase 3
panel provided by the IMPUTE2 authors (release October 2014), was used as the reference imputation
panel. Imputation probabilities (dosages) were converted to best-guess genotypes in fcGENE v1.07(18)
using a minimum probability threshold of 80% and a per-SNP missingness threshold of 5% of the sample.
After this process an INFO score cutoff of 0.8 was applied in order to select well-imputed variants, and all
monomorphic and singleton markers were excluded. With these filters 9.65 million biallelic markers
remained in the dataset.
Genotypes for the REGISTRY subjects were obtained from the GeM-HD Consortium (19), where details of
their genotyping, curation and imputation are provided. This dataset harboured 8.94 million biallelic markers
of 1,773 individuals (Figure 1).
Mixed linear model GWAS
Association analyses were performed with the mixed linear model (MLM) functions included in GCTA
v1.26(20), specifically the leave-one-chromosome-out (LOCO) procedure(21). As the genetic relationship
matrix used by MLMs can accurately account for cryptic relatedness and ancestry, and phenotypic variables
already controlled for relevant clinical covariates, no covariates were added to the analyses. In order to
transform the results into independent GWAS signals, PLINK was again used to perform linkage
disequilibrium (LD) clumping (r
2
= 0.1, p < 1x10
-4
; window size < 3 Mb). Due to the relatively small size of
the TRACK-HD and REGISTRY samples, calculation of SNP-based heritability (h
2
SNP) for our tested
phenotypes was not possible using either genotyped or imputed markers(22, 23). Because of the small
sample sizes, analyses were restricted to SNPs with minor allele frequency >1%.
Meta-analysis of the GWAS summary statistics from the TRACK-HD and REGISTRY studies was carried
out using the fixed effects method with inverse-variance weights as implemented in METAL (24). The
meta-analysis of TRACK-HD and REGISTRY studies was carried out using the fixed effects method with
inverse-variance weights as implemented in METAL(24). To control for spurious results due to scale
differences between the TRACK-HD and REGISTRY progression phenotypes, effect sizes from both
summary statistics were standardised to have equal variances before meta-analysis.
QQ plots of observed log p-values (sorted by value) for each SNP versus their expected values in the
absence of association are shown for TRACK-HD, REGISTRY and the meta-analysis in Supplementary
Figure 13. If there is no association, and no systematic inflation in the test statistics (for example, from
population stratification), the observed log p-values would follow their expected values (the red line in
Supplementary Figure 13) exactly. Indeed, this is what is observed for the majority of data points, which
do not show association. The extent to which such systematic inflation exists is measured by the genomic
95% confidence interval for log p-values in the absence of association is shaded grey, and the points lying
above this in the top right corner indicate genuine associations.
Conditional analyses of GWAS summary statistics were carried out using the COJO procedure included in
GCTA v1.26(26).
Co-localisation analyses
In order to discern if our top GWAS signals were mediated by the same SNPs in both TRACK-HD and
REGISTRY, we used the co-localisation method of Giambartolomei et al.(27), as implemented in GWAS-
pw v0.21 (28). In summary, the GWAS summary statistics of our two samples were first divided into
approximately independent LD blocks(29), and each block was then scanned to estimate the probability (in a
hierarchical Bayesian framework) of harbouring an association common to the two samples. In contrast to
the original algorithm, the model priors do not need to be pre-specified in GWAS-pw, as they are estimated
directly from the summary statistics. This implementation has been thoroughly tested by simulation and
applied to real data from heterogeneous sources (28). By testing the entire genome instead of a small number
of candidate regions arising from the GWAS clumps, we follow a conservative approach towards estimating
co-localisation, which also has the desirable property of allowing us to compare our candidates (to the
resolution of single SNPs) with every other region in the genome.
A similar procedure was used to test for co-localisation between the region on chromosome 5 containing
GWAS signal in TRACK-HD and REGISTRY and SNPs influencing expression (eQTLs), since this may
indicate which gene in an association region is causal. Given that eQTLs close to the gene (cis-eQTLs) tend
to replicate more reliably than those from other parts of the genome (30), these analyses were restricted to
the regions of GWAS signal and genes within 1Mb of these regions. These analyses used expression data
from 53 tissues, accessed through GTeX (31). To minimise multiple testing, the two tissues showing the
most significant eQTLs for each gene were used for the co-localisation analysis. Additionally, for DHFR
and MSH3, analyses were performed using three brain tissues (caudate, cerebellum and cortex), since these
are the most biologically relevant to HD a priori. Co-localisation results are shown for the TRACK-HD
GWAS in Supplementary Table 8, and the REGISTRY GWAS in Supplementary Table 9. Plots of
GWAS and eQTL signals with significant co-localisation are shown in in Supplementary Figures 7 and 8.
Gene-based and gene-set analyses
Gene-wide p-values were calculated using MAGMA v1.05 (32) on the TRACK-HD and REGISTRY
summary statistics, by summing the p-values of all SNPs inside each gene. MAGMA aggregates the
association evidence across all SNPs in a gene, while correcting for LD between SNPs (using the European
data from Phase 3 of the 1000 Genomes Project as reference). This analysis increases power when a gene
contains multiple causal SNPs (e.g. as a result of allelic heterogeneity), or when the causal SNP is not typed
and its signal is partially captured by multiple genotyped SNPs in LD with it. We set a window of 35 kb
upstream and 10 kb downstream of each gene in order to capture the signal of proximal regulatory SNPs(33,
34).
To maximise comparability with the GeM GWAS, our primary gene-set analyses used Setscreen (Moskvina
et al. 2011). Setscreen sums the (log-) p-values of all SNPs in the gene set, similar to Fishers method, but
adjusts the distribution to allow for non-independence of SNPs due to linkage disequilibrium (Brown 1975).
Significant enrichments from the Setscreen analyses were confirmed using the competitive gene-set analysis
procedure implemented in MAGMA. This more conservative approach tests whether genes in a gene set
have more significant gene-wide p-values than other genes, correcting for gene size, SNP density and
intergenic linkage disequilibrium (de Leeuw et al. 2015), but may be less powerful than the Setscreen
analysis for small gene sets.
Initially, we performed gene set analyses on the 14 pathways found to be significantly enriched for
association signal in the GeM GWAS. Many of these pathways relate to DNA repair, so we investigated the
biological specificity of this signal further by analysing 78 gene-sets taken from a recent review of DNA
repair (Pearl et al 2015).
As a secondary analysis, to potentially uncover areas of novel disease-related biology, we tested the same
gene sets used by GeM-HD Consortium (2015). This comprises a collection of 14,706 pathways containing
between 3 and 500 genes from the Gene Ontology (GO)(35), Kyoto Encyclopedia of Genes and Genomes
(KEGG)(36), Mouse Genome Informatics (MGI)(37), National Cancer Institute (NCI)(38), Protein ANalysis
THrough Evolutionary Relationships (PANTHER)(39), BioCarta(40) and Reactome(41). Multiple testing
correction was carried out for this analysis by calculating q-values (Storey and Tibshirani, 2003).
Linking genetic variation to clinical measures
To explain how our TRACK-HD lead variant (rs557874766) affected commonly used clinical measures of
HD severity we first correlated TRACK-HD progression score with UHDRS Total Motor Score (TMS) and
UHDRS Total Functional Capacity (TFC). We defined raw TMS rate as TMS change divided by follow-
up years and adjusted TMS rate as the residual of raw TMS rate after regressing off effects of initial TMS,
age, sex, CAG. We followed the same procedure for TFC.
Regressing these measures on progression gives the following estimates of the amount of change for one
unit increase in progression (standard errors in brackets):
Raw TMS rate: 0.71(0.19)
Adjusted TMS rate: 0.57 (0.18)
Raw TFC rate: 0.21 (0.047)
Adjusted TFC rate: 0.20 (0.044)
The effect size at the top MSH3 SNP in TRACK (rs557874766) is -0.58 (s.e. =0.087) units of progression
per copy of the minor allele G (see Supplementary Table 21)  this corresponds to a change of -0.33 (95%
CI =0.10, 0.56) to -0.41 (0.16,0.66) units in TMS rate compared to the major allele C, which can be
interpreted as a reduction in the rate of TMS increase by 0.33-0.41 units per year for each copy of the G
allele. Similarly, this corresponds to a reduction in the rate of TFC change of 0.12 (0.06,0.18) units per year
per G allele.
Results
SinceMSH3 is a member of all the most significantly enriched pathways, we tested whetherMSH3 was
individually responsible for the pathway enrichments by removing it and repeating the analyses. GO:32300
and KEGG:3430 are still nominally significant in TRACK (p=0.0413, p=0.0452 respectively) but not in
REGISTRY. Neither of the two Pearl pathways is significant in TRACK or REGISTRY. The only pathways
nominally significant both in TRACK and REGISTRY are GO:32389 (MutLalpha complex) and Pearl
pathway Repair_pathway/SSR/MMR/MutL_homologs, neither of which containMSH3. Thus, it appears
that the mismatch repair pathway enrichments are mainly driven byMSH3. However, in the TRACK-
REGISTRY meta-analysis, the Pearl et al. MMR pathway (p=1.27x10
-4
), GO:32300 (p=1.02x10
-3
), KEGG
3430 (1.07x10
-4
) and GO:30983 are at least nominally significant without MSH3. Pathway enrichments
without MSH3 are shown in Supplementary Table 18 for the 14 GeM pathways and Supplementary
Table 19 for the Pearl et al. pathways.
Setscreen gene set analysis of the large set of pathways analysed by the GeM-HD Consortium (2015) is
shown in Supplementary Table 24. There were 26 pathways showing significant (q<0.05) enrichment in
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TRACK after correction for multiple testing of pathways. These pathways mainly relate to DNA repair and
binding, and none is more significant than GO:32300 (mismatch repair complex). The genes in these 26
pathways are shown in Supplementary Table 25, and are similar to those in Tables 2 and 3, with the
exception of DHFR (however, the pathways containing DHFR tend to be less strongly associated than the
mismatch repair pathways in both TRACK and REGISTRY). Thus, analysis of the large set of pathways
does not appear to throw up any novel areas of biology outside those indicated by the GeM paper.
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Supplementary Figure 1: Observed versus Expected Age of Onset Among Those Who Have Experienced Onset in the TRACK-HD analysis: amongst these
96 subjects who had experienced onset, the rater AAO showed the expected relation with predicted AAO based on CAG length. Earlier than predicted onset
age was correlated with faster progression (using the unified HD progression measure) (r=-0·315; p = 0·002)
Supplementary Figure 2: REGISTRY progression measure and atypical onset age are modestly correlated in REGISTRY. Note bias for very late expected
onset for those with low CAG repeats. SD = Standard deviation.
Supplementary Figure 3: Regional plot of TRACK-HD
GWAS signal in the MSH3-DHFR region before(top) and
after (bottom) conditioning on the most significant SNP in
TRACK-HD (rs557874766). The lack of significant
association after conditioning on this SNP is consistent with
here being only one association signal in the region.
Supplementary Figure 4: Regional plot of TRACK-HD and REGISTRY
meta-analysis GWAS signal in the MSH3-DHFR region before(top) and
after (bottom) conditioning on the most significant SNP in the meta-
analysis (rs1232027). The lack of significant association after
conditioning on this SNP is consistent with here being only one
association signal in the region.
Supplementary Figure 5: Regional plot of TRACK-HD and REGISTRY
meta-analysis GWAS signal in the MSH3-DHFR region before(top) and
after (bottom) conditioning on the most significant SNP in TRACK-HD
(rs557874766). The lack of significant association after conditioning on
this SNP is consistent with here being only one association signal in the
region.
Supplementary Figure 6: Regional plot of REGISTRY GWAS signal in
the MSH3-DHFR region before(top) and after (bottom) conditioning on
the most significant SNP in TRACK-HD (rs557874766). The significance
of association is largely unaffected by conditioning on this SNP. This
indicates that rs557874766 does not explain the REGISTRY association
signal in this region.
Supplementary Figure 7: Regional plot of TRACK-HD
GWAS signal in the MSH3-DHFR region (top, red), along
with GTeX eQTL associations with DHFR expression in
(top-bottom) whole blood, skeletal muscle, cerebellum,
cortex.
Supplementary Figure 8: Regional plot of REGISTRY GWAS
signal in the MSH3-DHFR region (top, blue), along with GTeX
eQTL associations with MSH3 expression in (top-bottom) whole
blood, transformed fibroblasts.
Supplementary Figure 9: (A) Scree Plot and (B) Plot showing proportion of variance explained in the TRACK-HD progression principal component
analysis: the dominance of the first PC is illustrated.
Supplementary Figure 10: (A) Scree Plot and (B) Plot showing proportion of variance explained in the REGISTRY progression principal component
analysis: the dominance of the first PC is illustrated.
Supplementary Figure 11: Age-CAG severity function against clinical probability of onset (CPO) in REGISTRY. A: plot showing predicted values for all
subjects. B: plot of predicted values using only subjects in the CAG 41 55 range. C: Plot based on extrapolating the severity model to subjects with CAG in
the 36-40 range (the appearance of two rather distinct lines are due to the gender effect, with women having lower predicted scores than men).
A B C
Supplementary Figure 12: Linear relationship between the longitudinal atypical severity scores used for the TRACK-HD analysis and cross-sectional atypical
severity scores at the last TRACK visit when calculated using the method employed for the REGISTRY data (r = .674).
Supplementary Figure 13:
there is no systematic inflation of test statistics.
A
B
C
Supplementary tables:
Supplementary Table 1: Demographic details of TRACK-HD cohort.
Further detail can be found in Tabrizi et al 2009, 2011, 2012, 2013.
Number (female) Age at baseline (years) CAG repeat length
Manifest 122 (65) 48.0 43.5
Premanifest 96 (53) 40.6 43.0
Supplementary Table 2: List of Variables to be used in TRACK-HD progression analyses. Further
detail regarding these measures can be found in Tabrizi et al 2009, 2011, 2012, 2013.
Symbol digit modality test (number correct)
Stroop word reading (number correct)
Paced Tapping 3 Hz (inverse std dev)
Spot the Change 5K
Emotion Recognition
Direct Circle (Log annulus length)
Indirect Circle (Log annulus length)
Total brain volume
Ventricular volume
Grey matter volume
White matter volume
Caudate volume
Metronome tapping, nondominant hand
Metronome tapping, nondominant hand
Speeded tapping, nondominant hand
Speeded tapping, nondominant hand
Speeded tapping, nondominant hand
Tongue forceheavy
Tongue forcelight
Grip force, dom. hand, heavy condition
Grip force, dom. hand, heavy condition
Grip force, nondom. hand, heavy condition
Grip force, dom. hand, light condition
Grip force, nondom. hand, light condition
Supplementary Table 3: Correlations among Domain-Specific Residual Principal Components in
the TRACK-HD analysis, showing that the first principle components of each domain are
significantly correlated.
The prefaces brain, cog, and mot indicate the domain. The suffix f1, f2, etc, numbers the principal
components within each domain. Having approximated the residual longitudinal variability within each of the three
domains via principal components, we then examined cross-domain relationships among these components. For
example, after accounting for CAG-age-risk, testing whether residual longitudinal change in the brain measures
correlated with the Q-motor measures.
brainf1 brainf2 brainf3 cogf1 cogf2 cogf3 cogf4 motf1 motf2 motf3 motf4
brainf1 1 0 0 -0.355 0.077 0.146 -0.068 0.43 0.096 -0.065 -0.139
p 0 1 1 <.0001 0.26 0.03 0.32 <.0001 0.16 0.34 0.04
brainf2 0 1 0 -0.097 -0.055 0.12 -0.016 0.005 -0.149 -0.043 0.041
p 1 0 1 0.15 0.42 0.08 0.81 0.94 0.03 0.53 0.55
brainf3 0 0 1 0.016 0.064 0.12 -0.009 0.15 0.05 -0.108 -0.161
p 1 1 0 0.81 0.35 0.08 0.89 0.03 0.46 0.11 0.02
cogf1 1 0 0 0 -0.434 -0.154 0.035 0.112
p 0 1 1 1 <.0001 0.02 0.6 0.09
cogf2 0 1 0 0 0.035 0.07 -0.12 -0.163
p 1 0 1 1 0.59 0.29 0.07 0.01
cogf3 0 0 1 0 0.105 -0.017 -0.092 -0.143
p 1 1 0 1 0.11 0.8 0.16 0.03
cogf4 0 0 0 1 -0.019 -0.05 -0.011 -0.054
p 1 1 1 0 0.77 0.44 0.87 0.42
Supplementary Table 4: PCA of Residual Longitudinal Change Among Variables form All 3 Domains in
the TRACK-HD analysis showing that the variables that correlated with the domain specific analyses also
correlated with the common principal component analysis.
Measure PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8
Symbol Digit -0.505 -0.027 0.135 0.194 0.034 0.047 -0.394 -0.121
Stroop Word -0.391 -0.017 0.361 0.468 0.078 -0.232 0.087 0.123
Paced Tapping 3 Hz (inverse std dev) -0.054 -0.123 -0.031 -0.066 0.032 0.621 -0.420 0.233
Spot the Change 5K 0.224 -0.123 0.113 -0.223 -0.016 0.190 0.427 0.479
Emotion Recognition -0.226 0.188 0.228 0.086 -0.090 -0.415 0.098 0.264
Direct Circle (Log annulus length) -0.374 -0.101 0.419 0.199 0.488 0.258 0.060 -0.027
Indirect Circle (Log annulus length) -0.406 -0.076 0.407 0.418 0.161 0.336 0.036 0.130
Total brain volume 0.749 -0.457 0.168 0.077 -0.046 -0.100 -0.115 -0.079
Ventricular volume -0.545 0.509 -0.079 -0.125 0.094 0.131 0.274 0.043
Grey matter volume 0.631 -0.491 0.173 -0.050 -0.088 -0.137 0.038 -0.022
White matter volume 0.699 -0.409 0.252 -0.085 -0.019 -0.048 0.062 0.044
Caudate volume 0.584 -0.426 0.082 0.223 0.086 0.083 -0.055 0.046
Metronome tapping, nondominant hand 0.433 -0.033 -0.206 -0.338 0.104 0.392 0.037 -0.081
(log of tap initiation SD for all trials) 0.433 -0.033 -0.206 -0.338 0.104 0.392 0.037 -0.081
Metronome tapping, nondominant hand -0.033 -0.212 0.013 0.144 0.116 0.133 0.347 -0.705
(inv tap initiation SD for self-paced trials)
Speeded tapping, nondominant hand 0.380 -0.022 -0.483 0.315 0.554 -0.206 -0.058 0.123
(log of repetition time SD)
Speeded tapping, nondominant hand 0.594 0.028 -0.335 0.182 0.437 -0.061 0.027 0.206
(log of tap duration SD)
Speeded tapping, nondominant hand 0.316 0.373 -0.219 0.006 0.411 -0.036 -0.002 -0.120
(mean intertap time)
Tongue forceheavy 0.147 0.016 -0.332 0.586 -0.445 0.177 -0.033 0.012
(log coefficient of variation)
Tongue forcelight 0.247 0.114 -0.399 0.451 -0.407 0.191 0.217 0.066
(log coefficient of variation)
Grip force, dom. hand, heavy condition 0.615 0.488 0.252 0.009 -0.078 -0.014 -0.336 -0.077
(log of mean orientation)
Grip force, dom. hand, heavy condition 0.568 0.518 0.207 0.033 -0.027 -0.051 -0.381 -0.042
(log of mean position)
Grip force, nondom. hand, heavy condition 0.516 0.400 0.213 0.108 0.003 0.122 0.231 -0.145
(log of coefficient of variation)
Grip force, dom. hand, light condition 0.681 0.311 0.250 0.034 0.016 0.140 0.188 0.114
(log of coefficient of variation)
Grip force, nondom. hand, light condition 0.647 0.430 0.293 0.071 -0.061 0.071 0.163 -0.055
(log of coefficient of variation)
Pct Variance Explained 23.4 9.5 7.1 6 5.7 5.1 4.9 4.3
Supplementary Table 5: Factor pattern of the first two principal component analysis of the REGISTRY severity score
which was used as a progression score for the Registry data. Factor 1 = 1st PC; Factor 2 = 2nd PC.
Factor Pattern
Variable Variable explanation Factor1 Factor2
sqrtmotor Square root of the UHDRS total motor score -0.84233 0.30062
verfl UHDRS verbal fluency 0.79108 0.24136
sdmt UHDRS symbol digit score 0.89833 0.1522
scnt UHDRS Stroop color naming 0.89596 0.25872
swrt UHDRS Stroop word reading 0.88978 0.2109
sit1 UHDRS Stroop interference score 0.87684 0.21789
tfc UHDRS total functional capacity 0.8746 -0.39367
fasscore UHDRS functional assessment scale 0.88355 -0.38555
Supplementary Table 6: Independent association signals from the TRACK-HD Progression GWAS (at p-value < 10-5)
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0 2.694
0.58
2
3.70E-
06 1
0.00
1 BCLAF1, MTFR2
1 10849645 10849645 rs10864471 G A 0.076
0.99
6 0.798
0.17
3
3.85E-
06 1
0.00
1 CASZ1
16 84533672 85735002 rs544820106 T C 0.007
0.99
8 2.692
0.58
3
3.90E-
06 3
1201
.3
C16orf74, COTL1,
CRISPLD2,
FAM92B, GINS2,
GSE1, KIAA0513,
KLHL36,
LINC00311,
LOC400548,
MIR5093, MIR7851,
TLDC1, USP10,
ZDHHC7
9 140124101 140326510 rs576074352 T C 0.009
1.00
0 2.320
0.50
5
4.26E-
06 3
202.
41
C9orf169, C9orf173,
ENTPD8, EXD3,
FAM166A,
LOC100129722,
MIR7114, NDOR1,
NELFB, NOXA1,
NRARP, NSMF,
RNF208, RNF224,
SLC34A3, TOR4A,
TUBB4B
3 147917 147917 rs190854428 T C 0.014
0.99
0 1.920
0.41
8
4.29E-
06 1
0.00
1 none
7 20723109 20725291 rs78036476 G T 0.024
1.00
0 1.515
0.33
0
4.44E-
06 2
2.18
3 ABCB5
10 6409502 6409502 rs7915166 C T 0.308
1.00
0 0.496
0.10
8
4.80E-
06 1
0.00
1 none
4 178648851 178648851 rs191350537 A G 0.014
0.99
9 1.882
0.41
3
5.15E-
06 1
0.00
1 LINC01098
2 121177685 121177685 rs542948395 T C 0.009
1.00
0 2.291
0.50
4
5.37E-
06 1
0.00
1 none
19 40114782 40248603 rs544526021 T G 0.009
1.00
0 2.301
0.50
6
5.42E-
06 3
133.
82
CLC, LEUTX,
LGALS13,
LGALS14,
LGALS16,
LGALS17A,
LOC100129935
8 15256069 15266930 rs11203702 A T 0.118 0.99 0.680 0.15 5.56E- 3 10.8 none
6 0 06 62
7 126436990 126497288 rs139456699 A G 0.019
1.00
0 -1.608
0.35
4
5.74E-
06 3
60.2
99 GRM8
4 144227742 144227742 rs185067403 A G 0.009
1.00
0 2.294
0.50
6
5.80E-
06 1
0.00
1 none
13 20224902 20377448 rs35231784
G
C G 0.260
0.99
5 -0.495
0.11
0
6.11E-
06 36
152.
55 MPHOSPH8, PSPC1
3 71536485 71536485 rs139096029 A G 0.019
1.00
0 1.603
0.35
5
6.26E-
06 1
0.00
1 FOXP1
2 6216990 6265656 rs13017659 A C 0.068
0.97
5 0.818
0.18
1
6.28E-
06 4
48.6
67 none
8 141293251 141293251 rs186776689 T C 0.009
1.00
0 2.277
0.50
4
6.30E-
06 1
0.00
1 TRAPPC9
6 117738434 117812254 rs143087465 T C 0.009
1.00
0 2.289
0.50
7
6.42E-
06 3
73.8
21 DCBLD1, ROS1
1 71806741 71806741 rs615589 C T 0.017
0.95
3 1.772
0.39
3
6.45E-
06 1
0.00
1 none
1 34835613 34886817 rs10753307 C G 0.146
1.00
0 0.646
0.14
4
6.94E-
06 35
51.2
05 none
13 73610584 73624638 rs13378884 G A 0.280
1.00
0 0.500
0.11
1
7.28E-
06 2
14.0
55 KLF5, PIBF1
3 21479214 21521820 rs73045437 A G 0.131
0.99
6 0.683
0.15
2
7.32E-
06 2
42.6
07 ZNF385D
6 24188337 24301530 rs138968896 A C 0.047
0.99
8 1.058
0.23
6
7.39E-
06 21
113.
19 DCDC2
18 64640322 64640322 rs11663556 T C 0.009
0.99
7 2.246
0.50
5
8.55E-
06 1
0.00
1 none
16 21651427 21706726 rs139057628 C T 0.012
0.88
1 1.999
0.45
2
9.82E-
06 2 55.3
IGSF6, METTL9,
OTOA
11 122679684 122679684 rs5795348 G
G
A 0.201
0.98
7 0.587
0.13
3
9.91E-
06 1
0.00
1 UBASH3B
10 51520713 51520713 rs74922941 C T 0.016
1.00
0 1.701
0.38
5
9.92E-
06 1
0.00
1 TIMM23B
Supplementary Table 7: Independent association signals from the meta-analysis of TRACK-HD and
REGISTRY Progression GWAS (at p-value < 10-5)
Index SNP P-value Clump coordinates
Clump
size (KB) Gene(s) tagged
rs1232027 1.12E-10 chr5:79895438..80198404 302.967 DHFR, MSH3, MTRNR2L2
rs73786719 8.53E-07 chr6:147034576..147037984 3.409 ADGB
rs114688092 1.51E-06 chr3:47026101..47315538 289.438
CCDC12, KIF9, KIF9-AS1, KLHL18, NBEAL2,
NRADDP, SETD2
rs79029191 1.67E-06 chr18:8053863..8080538 26.676 PTPRM
rs932428 1.79E-06 chr20:37518361..37876772 358.412 DHX35, FAM83D, LOC339568, PPP1R16B
rs3889139 2.13E-06 chr11:6885429..6917038 31.61 OR2D2, OR10A2, OR10A4, OR10A5
rs114643193 2.65E-06 chr4:2844682..2939191 94.51 ADD1, MFSD10, NOP14, NOP14-AS1, SH3BP2
rs6882169 2.72E-06 chr5:167668230..167668230 0.001 CTB-178M22.2, TENM2
rs80260687 2.92E-06 chr8:97232364..97304966 72.603 MTERFD1, PTDSS1, UQCRB
rs28406206 3.13E-06 chr14:105680474..105688082 7.609 BRF1
rs4736525 3.37E-06 chr8:132924474..133030989 106.516 EFR3A, OC90
rs78621558 4.44E-06 chr5:80012735..80012735 0.001 MSH3
rs72715653 4.80E-06 chr4:178641337..178730329 88.993 LINC01098, LINC01099
rs4720024 4.94E-06 chr7:30941255..30942312 1.058 AQP1, FAM188B, INMT-FAM188B
rs117933444 5.75E-06 chr6:167362873..167410443 47.571 FGFR1OP, MIR3939, RNASET2
rs116220136 5.82E-06 chr5:23353255..23436446 83.192 none
rs8031584 8.15E-06 chr15:31185616..31292023 106.408 FAN1, MTMR10, TRPM1
rs3013648 9.10E-06 chr13:85296644..85374146 77.503 none
rs11197481 9.12E-06 chr10:117708803..117708803 0.001 ATRNL1
rs117440785 9.15E-06 chr10:17411451..17531334 119.884 ST8SIA6, ST8SIA6-AS1
rs111258354 9.87E-06 chr2:60823224..60883232 60.009 none
Supplementary Table 8: Co-localisation between TRACK-HD GWAS signal on chromosome 5 and
GTeX eQTLs for MSH3, DHFR
Dataset
Dataset
source
Most significant eQTL
p-value N Overlapping SNPs
COLOC probability (of
shared variants)
MSH3 (Blood) GTEx 1.70E-28 647 1.76%
MSH3 (Fibroblasts) GTEx 3.10E-39 646 1.76%
MSH3 (Cerebellum) GTEx 1.10E-06 592 8.83%
MSH3 (Caudate) GTEx 1.65E-05 588 25.20%
MSH3 (Cortex) GTEx 5.53E-05 582 53.10%
DHFR (Blood) GTEx 5.20E-45 647 98.10%
DHFR (Skeletal muscle) GTEx 1.30E-68 655 99.20%
DHFR (Cerebellum) GTEx 7.60E-13 592 28.30%
DHFR (Caudate) GTEx 2.60E-12 588 99.00%
DHFR (Cortex) GTEx 4.90E-15 582 96.10%
Supplementary Table 9: Co-localisation between REGISTRY GWAS signal on chromosome 5 and
GTeX eQTLs for MSH3, DHFR
Dataset
Dataset
source
Most significant eQTL
p-value N Common SNPs
COLOC probability (of
shared variants)
MSH3 (Blood) GTEx 1.70E-28 3289 97.80%
MSH3 (Fibroblasts) GTEx 3.10E-39 3224 97.80%
MSH3 (Cerebellum) GTEx 1.10E-06 2888 12.50%
MSH3 (Caudate) GTEx 1.65E-05 2866 10.40%
MSH3 (Cortex) GTEx 5.53E-05 2853 23.10%
DHFR (Blood) GTEx 5.20E-45 3289 36.40%
DHFR (Skeletal muscle) GTEx 1.30E-68 3336 34.10%
DHFR (Cerebellum) GTEx 7.60E-13 2888 0.88%
DHFR (Caudate) GTEx 2.60E-12 2866 43.30%
DHFR (Cortex) GTEx 4.90E-15 2853 23.10%
Supplementary Table 10: Co-localisation between TRACK-HD GWAS signal on chromosome 5 and
GTeX eQTLs for MSH3, DHFR
Dataset
Dataset
source
Most significant eQTL
p-value N Overlapping SNPs
COLOC probability (of
shared variants)
MSH3 (Blood) GTEx 1.70E-28 647 1.76%
MSH3 (Fibroblasts) GTEx 3.10E-39 646 1.76%
MSH3 (Cerebellum) GTEx 1.10E-06 592 8.83%
MSH3 (Caudate) GTEx 1.65E-05 588 25.20%
MSH3 (Cortex) GTEx 5.53E-05 582 53.10%
DHFR (Blood) GTEx 5.20E-45 647 98.10%
DHFR (Skeletal muscle) GTEx 1.30E-68 655 99.20%
DHFR (Cerebellum) GTEx 7.60E-13 592 28.30%
DHFR (Caudate) GTEx 2.60E-12 588 99.00%
DHFR (Cortex) GTEx 4.90E-15 582 96.10%
Supplementary Table 11: Independent association signals from the REGISTRY Progression GWAS (at p-value < 10-5)
Chr
omo
som
e Start (BP) End (BP)
Index SNP
(dbSNP b146)
Ref
ere
nce
Alle
le
(A1
)
Altern
ate
Allele
(A2)
Minor
Allele
Frequ
ency
(MAF
)
INFO
score Beta
Stand
ard
Error P-value
Nu
mb
er
of
SN
Ps
Length
(KB) Gene(s) tagged (+/- 20 KB)
10 117708803 117708803 rs11197481 A G
0.17
6
0.99
7 0.193
0.03
7 2.14E-07 1 0.001 ATRNL1
15 30996093 31314317 rs10611148 A
AAG
TT
0.27
4
0.99
9 0.160
0.03
1 2.84E-07 72
318.22
5
FAN1, HERC2P10,
LOC100288637,
MTMR10, TRPM1
6 67807895 67905502 rs75695330 C T
0.26
8
0.52
2 0.176
0.03
4 2.88E-07 12 97.608 none
12 117967637 117989548 rs10774933 C T
0.19
7
0.99
2 0.171
0.03
5 1.08E-06 10 21.912 KSR2
3 86317394 86321260 rs78656706 A G
0.02
5
0.61
0 -0.440
0.09
1 1.15E-06 2 3.867 none
1 151576174 151614297
rs76171298
0 A
AAT
AAA
T
0.08
9
0.85
8 -0.231
0.04
9 2.21E-06 3 38.124 SNX27
3 93566149 93725515 rs62266135 T G
0.01
5
0.50
0 0.542
0.11
6 2.77E-06 2
159.36
7
ARL13B, PROS1,
STX19
5 23353255 23436446 rs72754785 G A
0.04
5
0.90
8 0.316
0.06
7 2.87E-06 4 83.192 none
5 36704641 36954077 rs62356368 T G
0.01
6
0.98
5 0.531
0.11
4 2.92E-06 4
249.43
7
LOC646719, NIPBL,
SLC1A3
20 13209795 13245958
rs75990141
6 T
TCT
CTT
0.15
6
0.85
7 0.183
0.03
9 3.33E-06 3 36.164 ISM1, ISM1-AS1
10 6403262 6407737 rs2387399 T C
0.35
8
0.99
7 0.136
0.02
9 3.42E-06 2 4.476 none
14 33262946 33284981 rs991550 G A
0.07
7
0.99
6 -0.248
0.05
4 3.60E-06 3 22.036 AKAP6
10 85432343 85432343
rs14055051
0 G C
0.01
4
0.84
9 0.549
0.11
9 4.00E-06 1 0.001 none
15 92882676 92897269
rs14527168
3 T C
0.02
1
0.90
8 -0.450
0.09
8 4.65E-06 4 14.594 none
4 3860844 3863228 rs28501173 T G
0.27
0
0.99
7 0.145
0.03
2 4.66E-06 15 2.385 none
12 117075057 117079318
rs14485439
6 T TC
0.33
1
0.89
0 0.135
0.03
0 6.01E-06 8 4.262 none
16 6945437 6945437
rs18873831
6 A G
0.11
8
0.65
2 0.205
0.04
5 6.22E-06 1 0.001 RBFOX1
5 81062170 81062170 rs4703843 G T
0.16
5
0.91
5 0.172
0.03
8 6.27E-06 1 0.001 SSBP2
11 62532798 62614506 rs41542313 T C
0.03
1
0.99
9 0.367
0.08
1 6.31E-06 3 81.709
MIR6514, MIR6748,
NXF1, POLR2G,
SLC3A2, SNHG1,
SNORD22, SNORD25,
SNORD26, SNORD27,
SNORD28, SNORD29,
SNORD30, SNORD31,
STX5, TAF6L,
TMEM179B,
TMEM223, WDR74,
ZBTB3
21 45715620 45734831 rs3746965 A G
0.23
5
1.00
0 0.150
0.03
3 6.75E-06 4 19.212 AIRE, C21orf2, PFKL
3 49451639 52028491 rs28587738 A C
0.01
4
0.56
3 0.555
0.12
4 7.54E-06 5
2576.8
5
ABHD14A,
ABHD14A-ACY1,
ABHD14B, ACY1,
AMIGO3, AMT,
APEH, BSN, BSN-
AS2, C3orf18,
CACNA2D2, CAMKV,
CDHR4, CISH,
CYB561D2, DAG1,
DOCK3, FAM212A,
GMPPB, GNAI2,
GNAT1, GPR62,
GRM2, HEMK1,
HYAL1, HYAL2,
HYAL3, IFRD2,
IP6K1, IQCF1, IQCF2,
IQCF3, IQCF4, IQCF5,
IQCF5-AS1, IQCF6,
LSMEM2, MANF,
MAPKAPK3,
MIR4787, MIR5193,
MIR5787, MIR6872,
MON1A, MST1,
MST1R, NAT6,
NICN1, NPRL2,
PARP3, PCBP4,
RAD54L2, RASSF1,
RASSF1-AS1, RBM5,
RBM5-AS1, RBM6,
RBM15B, RHOA,
RNF123, RPL29,
RRP9, SEMA3B,
SEMA3B-AS1,
SEMA3F, SLC38A3,
TCTA, TEX264,
TMEM115, TRAIP,
TUSC2, UBA7,
VPRBP, ZMYND10
15 31126401 31276476 rs7180337 G T
0.02
0
0.62
1 -0.442
0.09
9 7.77E-06 22
150.07
6
FAN1, HERC2P10,
MTMR10, TRPM1
15 31345498 31367837 rs28632121 C T
0.24
7
0.99
8 -0.144
0.03
2 7.96E-06 8 22.34 MIR211, TRPM1
5 158949420 158950938
rs11555336
5 G T
0.02
0
0.79
9 0.450
0.10
1 8.58E-06 2 1.519 none
19 17164401 17164401 rs73022346 T G
0.01
3
0.64
9 -0.550
0.12
4 8.93E-06 1 0.001 HAUS8
7 70111666 70238809 rs80237739 C T
0.02
5
0.85
0 -0.405
0.09
2 9.80E-06 4
127.14
4 AUTS2
Supplementary Table 12: Gene-wide p-values in TRACK-HD, REGISTRY, the TRACK-REGISTRY meta-analysis and
GeM for all genes in the top 14 pathways from GeM
Pathway
Entr
ez
Gene
Symbol
Ch
r Start End
p(TRAC
K)
p(REGI
STRY)
p(META
) p(GeM) Description
GO:32300 4437 MSH3 5 79950467 80172634 2.94E-08 9.52E-04 8.88E-11 2.03E-02 mismatch repair complex
GO:30983 4437 MSH3 5 79950467 80172634 2.94E-08 9.52E-04 8.88E-11 2.03E-02 mismatched DNA binding
GO:6298 4437 MSH3 5 79950467 80172634 2.94E-08 9.52E-04 8.88E-11 2.03E-02 mismatch repair
KEGG
3430 4437 MSH3 5 79950467 80172634 2.94E-08 9.52E-04 8.88E-11 2.03E-02 KEGG_MISMATCH_REPAIR
KEGG
3430 5425 POLD2 7 44154279 44163169 7.21E-04 3.12E-01 2.75E-03 5.20E-01 KEGG_MISMATCH_REPAIR
KEGG
3430 3978 LIG1 19 48618703 48673560 1.65E-02 8.28E-02 5.35E-04 6.51E-02 KEGG_MISMATCH_REPAIR
KEGG
3430
2703
0 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.59E-03 KEGG_MISMATCH_REPAIR
GO:6298
2703
0 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.59E-03 mismatch repair
GO:32407
2703
0 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.59E-03 MutSalpha complex binding
GO:32300
2703
0 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.59E-03 mismatch repair complex
GO:30983
2703
0 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.59E-03 mismatched DNA binding
GO:10822 5534 PPP3R1 2 68405989 68479651 1.82E-02 4.76E-01 6.12E-01 8.40E-01
positive regulation of
mitochondrion organization
GO: 33683 2068 ERCC2 19 45854649 45873845 2.03E-02 8.83E-01 3.45E-01 7.45E-01
nucleotide-excision repair, DNA
incision
GO: 90200
8433
4 APOPT1 14 104029299 104057236 2.51E-02 8.19E-01 4.40E-01 8.18E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
8433
4 APOPT1 14 104029299 104057236 2.51E-02 8.19E-01 4.40E-01 8.18E-01
positive regulation of
mitochondrion organization
GO: 32389 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 MutLalpha complex
GO: 32300 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 mismatch repair complex
GO: 30983 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 mismatched DNA binding
KEGG
3430 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 KEGG_MISMATCH_REPAIR
GO: 6298 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 mismatch repair
GO: 32407 5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.91E-05 MutSalpha complex binding
GO: 30983 4439 MSH5 6 31707725 31730455 4.35E-02 8.54E-01 7.73E-01 5.14E-01 mismatched DNA binding
GO: 6298 4439 MSH5 6 31707725 31730455 4.35E-02 8.54E-01 7.73E-01 5.14E-01 mismatch repair
KEGG
3430 5982 RFC2 7 73645832 73668738 4.80E-02 5.91E-01 2.02E-02 4.46E-01 KEGG_MISMATCH_REPAIR
GO: 30983 7508 XPC 3 14186647 14220172 5.52E-02 1.04E-01 2.77E-02 5.53E-01 mismatched DNA binding
KEGG
3430 6119 RPA3 7 7676575 7758238 6.55E-02 7.22E-01 9.17E-02 4.40E-01 KEGG_MISMATCH_REPAIR
GO: 32300 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 mismatch repair complex
GO: 6298 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 mismatch repair
KEGG
3430 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 KEGG_MISMATCH_REPAIR
GO: 30983 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 mismatched DNA binding
GO: 32407 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 MutSalpha complex binding
GO: 32389 4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 4.13E-04 MutLalpha complex
GO: 33683 2067 ERCC1 19 45910591 45927177 7.32E-02 3.96E-01 2.69E-01 3.30E-01
nucleotide-excision repair, DNA
incision
GO: 32407 545 ATR 3 142168077 142297668 7.62E-02 7.94E-01 2.71E-01 2.97E-01 MutSalpha complex binding
GO: 90140
7959
4 MUL1 1 20825941 20834674 8.94E-02 5.22E-01 5.27E-01 4.68E-01
regulation of mitochondrial
fission
GO: 90141
7959
4 MUL1 1 20825941 20834674 8.94E-02 5.22E-01 5.27E-01 4.68E-01
positive regulation of
mitochondrial fission
GO: 10822
7959
4 MUL1 1 20825941 20834674 8.94E-02 5.22E-01 5.27E-01 4.68E-01
positive regulation of
mitochondrion organization
GO: 90200
2635
5
FAM162
A 3 122103023 122128961 1.32E-01 7.57E-01 6.93E-01 8.40E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
2635
5
FAM162
A 3 122103023 122128961 1.32E-01 7.57E-01 6.93E-01 8.40E-01
positive regulation of
mitochondrion organization
GO:190006
3
5694
7 MFF 2 228192228 228222549 1.52E-01 9.63E-01 5.92E-01 3.29E-01
regulation of peroxisome
organization
GO: 10822
5694
7 MFF 2 228192228 228222549 1.52E-01 9.63E-01 5.92E-01 3.29E-01
positive regulation of
mitochondrion organization
GO: 90200
5694
7 MFF 2 228192228 228222549 1.52E-01 9.63E-01 5.92E-01 3.29E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 32389 7486 WRN 8 30890778 31031277 1.66E-01 5.59E-01 6.60E-01 3.60E-01 MutLalpha complex
GO: 32300 7486 WRN 8 30890778 31031277 1.66E-01 5.59E-01 6.60E-01 3.60E-01 mismatch repair complex
GO: 10822 637 BID 22 18216906 18257431 1.77E-01 2.99E-02 7.33E-02 2.11E-01
positive regulation of
mitochondrion organization
GO: 90200 637 BID 22 18216906 18257431 1.77E-01 2.99E-02 7.33E-02 2.11E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 90141
5470
8
MARCH
_5 10 94050920 94113721 1.81E-01 8.26E-03 4.51E-01 5.33E-02
positive regulation of
mitochondrial fission
GO: 10822
5470
8
MARCH
_5 10 94050920 94113721 1.81E-01 8.26E-03 4.51E-01 5.33E-02
positive regulation of
mitochondrion organization
GO: 90140
5470
8
MARCH
_5 10 94050920 94113721 1.81E-01 8.26E-03 4.51E-01 5.33E-02
regulation of mitochondrial
fission
KEGG
3430
2993
5 RPA4 23 96138907 96140466 1.81E-01 N/A N/A N/A KEGG_MISMATCH_REPAIR
GO: 10822 572 BAD 11 64037300 64052176 1.87E-01 2.48E-01 4.16E-01 1.79E-01
positive regulation of
mitochondrion organization
GO: 90200 572 BAD 11 64037300 64052176 1.87E-01 2.48E-01 4.16E-01 1.79E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 33683 2071 ERCC3 2 128014866 128051752 1.97E-01 4.27E-01 8.61E-01 7.39E-03
nucleotide-excision repair, DNA
incision
GO:
10822 708 C1QBP 17 5336099 5342471 2.05E-01 8.72E-01 2.59E-01 5.99E-01
positive regulation of
mitochondrion organization
GO:190006
3
5750
6 MAVS 20 3827446 3856770 2.13E-01 7.14E-02 2.31E-01 8.82E-01
regulation of peroxisome
organization
GO: 10822 5366 PMAIP1 18 57567192 57571538 2.38E-01 1.05E-01 2.58E-02 1.10E-01
positive regulation of
mitochondrion organization
GO: 90200 5366 PMAIP1 18 57567192 57571538 2.38E-01 1.05E-01 2.58E-02 1.10E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 90200
2910
8
PYCAR
D 16 31212807 31214097 2.44E-01 4.42E-01 1.57E-01 N/A
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
2910
8
PYCAR
D 16 31212807 31214097 2.44E-01 4.42E-01 1.57E-01 N/A
positive regulation of
mitochondrion organization
GO: 30983 2956 MSH6 2 48010221 48034092 2.46E-01 3.15E-01 1.58E-01 9.36E-02 mismatched DNA binding
GO: 32300 2956 MSH6 2 48010221 48034092 2.46E-01 3.15E-01 1.58E-01 9.36E-02 mismatch repair complex
KEGG
3430 2956 MSH6 2 48010221 48034092 2.46E-01 3.15E-01 1.58E-01 9.36E-02 KEGG_MISMATCH_REPAIR
GO: 6298 2956 MSH6 2 48010221 48034092 2.46E-01 3.15E-01 1.58E-01 9.36E-02 mismatch repair
GO: 10822
5110
0
SH3GLB
1 1 87170253 87213867 2.55E-01 7.63E-01 2.92E-01 5.27E-01
positive regulation of
mitochondrion organization
GO: 90141 664 BNIP3 10 133781204 133795435 2.63E-01 1.17E-01 7.70E-01 7.19E-01
positive regulation of
mitochondrial fission
GO: 90140 664 BNIP3 10 133781204 133795435 2.63E-01 1.17E-01 7.70E-01 7.19E-01
regulation of mitochondrial
fission
GO:
10822 664 BNIP3 10 133781204 133795435 2.63E-01 1.17E-01 7.70E-01 7.19E-01
positive regulation of
mitochondrion organization
GO: 90200 664 BNIP3 10 133781204 133795435 2.63E-01 1.17E-01 7.70E-01 7.19E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 32407 4595 MUTYH 1 45794914 45806142 2.75E-01 4.31E-01 1.97E-01 1.97E-01 MutSalpha complex binding
GO: 6298 4595 MUTYH 1 45794914 45806142 2.75E-01 4.31E-01 1.97E-01 1.97E-01 mismatch repair
GO: 10822 2810 SFN 1 27189633 27190947 2.78E-01 4.30E-01 2.23E-01 7.65E-01
positive regulation of
mitochondrion organization
KEGG
3430 5424 POLD1 19 50887580 50921275 2.84E-01 6.48E-01 6.86E-01 2.11E-01 KEGG_MISMATCH_REPAIR
KEGG
3430 6118 RPA2 1 28218049 28241236 2.94E-01 2.04E-02 1.18E-01 7.45E-01 KEGG_MISMATCH_REPAIR
GO: 6298 2072 ERCC4 16 14014014 14046205 3.00E-01 5.58E-01 2.66E-01 6.21E-01 mismatch repair
GO: 33683 2072 ERCC4 16 14014014 14046205 3.00E-01 5.58E-01 2.66E-01 6.21E-01
nucleotide-excision repair, DNA
incision
KEGG
3430 5983 RFC3 13 34392206 34540695 3.15E-01 7.80E-01 7.18E-01 6.12E-01 KEGG_MISMATCH_REPAIR
GO: 90200 7157 TP53 17 7571720 7590868 3.21E-01 5.79E-01 2.20E-01 2.47E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822 7157 TP53 17 7571720 7590868 3.21E-01 5.79E-01 2.20E-01 2.47E-01
positive regulation of
mitochondrion organization
GO: 10822 207 AKT1 14 105235686 105262080 3.62E-01 4.10E-01 5.64E-01 3.96E-01
positive regulation of
mitochondrion organization
KEGG
3430 5981 RFC1 4 39289069 39368001 3.64E-01 6.29E-01 7.60E-01 6.19E-01 KEGG_MISMATCH_REPAIR
GO: 90200 581 BAX 19 49458117 49465055 3.65E-01 1.25E-01 2.47E-01 8.13E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822 581 BAX 19 49458117 49465055 3.65E-01 1.25E-01 2.47E-01 8.13E-01
positive regulation of
mitochondrion organization
GO: 90200
9042
7 BMF 15 40380091 40401075 3.71E-01 5.25E-02 3.21E-02 5.08E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
9042
7 BMF 15 40380091 40401075 3.71E-01 5.25E-02 3.21E-02 5.08E-01
positive regulation of
mitochondrion organization
GO: 10822
1089
1
PPARGC
1A 4 23793644 23891700 3.79E-01 1.49E-01 1.47E-01 3.43E-01
positive regulation of
mitochondrion organization
GO: 10822
6501
8 PINK1 1 20959948 20978004 3.83E-01 8.71E-01 5.33E-01 4.83E-01
positive regulation of
mitochondrion organization
GO: 90200
6501
8 PINK1 1 20959948 20978004 3.83E-01 8.71E-01 5.33E-01 4.83E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 90200
1096
2 MLLT11 1 151032151 151040973 3.90E-01 7.62E-01 9.23E-01 4.75E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
1096
2 MLLT11 1 151032151 151040973 3.90E-01 7.62E-01 9.23E-01 4.75E-01
positive regulation of
mitochondrion organization
GO: 32300 4436 MSH2 2 47630206 47710367 3.98E-01 3.10E-01 7.03E-01 5.49E-01 mismatch repair complex
GO: 30983 4436 MSH2 2 47630206 47710367 3.98E-01 3.10E-01 7.03E-01 5.49E-01 mismatched DNA binding
GO: 6298 4436 MSH2 2 47630206 47710367 3.98E-01 3.10E-01 7.03E-01 5.49E-01 mismatch repair
KEGG
3430 4436 MSH2 2 47630206 47710367 3.98E-01 3.10E-01 7.03E-01 5.49E-01 KEGG_MISMATCH_REPAIR
GO: 10822 841 CASP8 2 202098166 202152434 4.15E-01 8.81E-01 4.49E-01 3.35E-01
positive regulation of
mitochondrion organization
GO: 10822 7533 YWHAH 22 32340479 32353590 4.25E-01 7.16E-01 2.86E-01 6.25E-01
positive regulation of
mitochondrion organization
GO: 10822 8655 DYNLL1 12 120907660 120936298 4.50E-01 3.11E-01 4.07E-01 4.21E-01
positive regulation of
mitochondrion organization
GO: 32407 5378 PMS1 2 190648811 190742355 4.57E-01 8.23E-01 3.36E-01 7.24E-02 MutSalpha complex binding
GO: 32389 5378 PMS1 2 190648811 190742355 4.57E-01 8.23E-01 3.36E-01 7.24E-02 MutLalpha complex
GO: 32300 5378 PMS1 2 190648811 190742355 4.57E-01 8.23E-01 3.36E-01 7.24E-02 mismatch repair complex
GO: 30983 5378 PMS1 2 190648811 190742355 4.57E-01 8.23E-01 3.36E-01 7.24E-02 mismatched DNA binding
GO: 6298 5378 PMS1 2 190648811 190742355 4.57E-01 8.23E-01 3.36E-01 7.24E-02 mismatch repair
GO: 33683 2073 ERCC5 13 103498191 103528351 4.73E-01 7.10E-01 3.43E-01 2.62E-01
nucleotide-excision repair, DNA
incision
GO: 10822 7755 ZNF205 16 3162563 3170518 4.74E-01 9.01E-01 7.24E-01 9.47E-01
positive regulation of
mitochondrion organization
GO:90200 8743
TNFSF1
0 3 172223298 172241297 4.77E-01 6.95E-01 6.77E-01 6.09E-01
positive regulation of release of
cytochrome c from mitochondria
GO:10822 8743
TNFSF1
0 3 172223298 172241297 4.77E-01 6.95E-01 6.77E-01 6.09E-01
positive regulation of
mitochondrion organization
KEGG
3430 6742 SSBP1 7 141438121 141450288 4.81E-01 8.18E-01 8.67E-01 5.17E-01 KEGG_MISMATCH_REPAIR
GO:10822
2895
8 COA3 17 40949652 40950704 4.87E-01 1.75E-03 5.11E-01 N/A
positive regulation of
mitochondrion organization
GO:6298
1127
7 TREX1 3 48506919 48509044 4.91E-01 4.76E-01 7.94E-01 4.11E-01 mismatch repair
GO:32407
1127
7 TREX1 3 48506919 48509044 4.91E-01 4.76E-01 7.94E-01 4.11E-01 MutSalpha complex binding
GO:33683
2290
9 FAN1 15 31196055 31235311 5.30E-01 2.16E-06 1.15E-04 2.10E-09
nucleotide-excision repair, DNA
incision
GO:10822
1057
2 SIVA1 14 105219470 105225996 5.32E-01 1.48E-01 6.74E-01 8.89E-01
positive regulation of
mitochondrion organization
GO:6298 9156 EXO1 1 242011493 242053241 5.56E-01 9.35E-01 9.03E-01 2.23E-01 mismatch repair
KEGG
3430 9156 EXO1 1 242011493 242053241 5.56E-01 9.35E-01 9.03E-01 2.23E-01 KEGG_MISMATCH_REPAIR
GO: 90200
1010
5 PPIF 10 81107220 81115090 5.62E-01 2.02E-01 4.28E-01 4.88E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
1010
5 PPIF 10 81107220 81115090 5.62E-01 2.02E-01 4.28E-01 4.88E-01
positive regulation of
mitochondrion organization
GO: 6298 7161 TP73 1 3569129 3652765 5.69E-01 3.18E-01 4.40E-01 5.54E-01 mismatch repair
GO:10822 7531 YWHAE 17 1247834 1303556 5.70E-01 8.16E-01 4.96E-01 5.15E-01
positive regulation of
mitochondrion organization
GO: 10822 7532 YWHAG 7 75956108 75988342 5.78E-01 4.82E-01 9.74E-01 8.36E-02
positive regulation of
mitochondrion organization
GO: 10822 7534 YWHAZ 8 101930804 101965623 5.89E-01 1.51E-01 1.89E-01 5.93E-02
positive regulation of
mitochondrion organization
GO: 90140
6442
3 INF2 14 105155943 105185947 5.93E-01 2.11E-01 2.83E-01 5.52E-01
regulation of mitochondrial
fission
GO: 10822 578 BAK1 6 33540323 33548070 5.98E-01 7.98E-01 7.78E-01 3.03E-01
positive regulation of
mitochondrion organization
GO: 90200 578 BAK1 6 33540323 33548070 5.98E-01 7.98E-01 7.78E-01 3.03E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 33683 4913 NTHL1 16 2089816 2097867 6.25E-01 5.50E-01 4.66E-01 6.35E-01
nucleotide-excision repair, DNA
incision
GO: 90200
1001
8
BCL2L1
1 2 111878491 111926022 6.27E-01 8.58E-01 8.05E-01 1.51E-02
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
1001
8
BCL2L1
1 2 111878491 111926022 6.27E-01 8.58E-01 8.05E-01 1.51E-02
positive regulation of
mitochondrion organization
GO: 10822 4836 NMT1 17 43138680 43186384 6.37E-01 9.42E-01 9.35E-01 4.65E-01
positive regulation of
mitochondrion organization
GO: 10822
1097
1 YWHAQ 2 9724106 9771106 6.38E-01 1.92E-01 6.28E-01 7.69E-01
positive regulation of
mitochondrion organization
GO: 10822 7529 YWHAB 20 43514344 43537161 6.50E-01 2.53E-01 4.98E-01 8.31E-01
positive regulation of
mitochondrion organization
GO: 6298
1071
4 POLD3 11 74303575 74354105 6.51E-01 8.79E-01 6.36E-01 1.52E-01 mismatch repair
KEGG
3430
1071
4 POLD3 11 74303575 74354105 6.51E-01 8.79E-01 6.36E-01 1.52E-01 KEGG_MISMATCH_REPAIR
GO: 30983 6996 TDG 12 104359593 104382656 6.84E-01 1.83E-01 2.10E-01 4.78E-01 mismatched DNA binding
GO: 6298 6996 TDG 12 104359593 104382656 6.84E-01 1.83E-01 2.10E-01 4.78E-01 mismatch repair
GO: 90140 1723 DHODH 16 72042643 72059316 6.96E-01 9.59E-01 7.30E-01 4.85E-01
regulation of mitochondrial
fission
GO: 6298 25 ABL1 9 133589268 133763062 6.97E-01 6.47E-01 9.21E-01 1.81E-01 mismatch repair
GO: 30983 4438 MSH4 1 76262556 76378923 7.24E-01 2.05E-01 2.13E-01 1.40E-01 mismatched DNA binding
KEGG
3430 5985 RFC5 12 118454506 118470044 7.38E-01 1.15E-01 2.33E-01 3.95E-01 KEGG_MISMATCH_REPAIR
GO:190006
3
1005
9 DNM1L 12 32832137 32898584 7.55E-01 8.32E-01 6.94E-01 1.36E-03
regulation of peroxisome
organization
GO: 90141
1005
9 DNM1L 12 32832137 32898584 7.55E-01 8.32E-01 6.94E-01 1.36E-03
positive regulation of
mitochondrial fission
GO: 90200
1005
9 DNM1L 12 32832137 32898584 7.55E-01 8.32E-01 6.94E-01 1.36E-03
positive regulation of release of
cytochrome c from mitochondria
GO: 10822
1005
9 DNM1L 12 32832137 32898584 7.55E-01 8.32E-01 6.94E-01 1.36E-03
positive regulation of
mitochondrion organization
GO: 90140
1005
9 DNM1L 12 32832137 32898584 7.55E-01 8.32E-01 6.94E-01 1.36E-03
regulation of mitochondrial
fission
KEGG
3430 6117 RPA1 17 1733273 1802848 7.75E-01 2.96E-01 5.51E-01 4.76E-01 KEGG_MISMATCH_REPAIR
GO: 10822 5533 PPP3CC 8 22298483 22398657 7.99E-01 4.58E-01 7.29E-01 3.38E-01
positive regulation of
mitochondrion organization
KEGG
3430 5984 RFC4 3 186507681 186524484 8.08E-01 7.04E-01 7.95E-01 3.01E-01 KEGG_MISMATCH_REPAIR
GO: 4748 6240 RRM1 11 4115924 4160106 8.20E-01 6.60E-01 9.85E-01 3.40E-01
ribonucleoside-diphosphate
reductase activity, thioredoxin
disulfide as acceptor
GO: 16728 6240 RRM1 11 4115924 4160106 8.20E-01 6.60E-01 9.85E-01 3.40E-01
oxidoreductase activity, acting
on CH or CH2 groups, disulfide
as acceptor
GO: 30983 5111 PCNA 20 5095599 5107268 8.29E-01 2.76E-01 6.40E-01 3.55E-01 mismatched DNA binding
KEGG
3430 5111 PCNA 20 5095599 5107268 8.29E-01 2.76E-01 6.40E-01 3.55E-01 KEGG_MISMATCH_REPAIR
GO: 6298 5111 PCNA 20 5095599 5107268 8.29E-01 2.76E-01 6.40E-01 3.55E-01 mismatch repair
GO: 90200 638 BIK 22 43506754 43525718 8.52E-01 6.42E-01 8.52E-01 1.19E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822 638 BIK 22 43506754 43525718 8.52E-01 6.42E-01 8.52E-01 1.19E-01
positive regulation of
mitochondrion organization
GO: 10822 596 BCL2 18 60790579 60986613 8.65E-01 5.93E-01 4.81E-01 6.54E-01
positive regulation of
mitochondrion organization
GO: 10822 3002 GZMB 14 25100160 25103432 8.84E-01 8.26E-01 8.18E-01 6.33E-01
positive regulation of
mitochondrion organization
GO: 10822
2711
3 BBC3 19 47724079 47736023 8.89E-01 4.98E-01 7.87E-01 2.78E-01
positive regulation of
mitochondrion organization
GO: 90200
2711
3 BBC3 19 47724079 47736023 8.89E-01 4.98E-01 7.87E-01 2.78E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 16728 6241 RRM2 2 10262695 10271546 8.96E-01 3.35E-01 3.69E-01 2.65E-01
oxidoreductase activity, acting
on CH or CH2 groups, disulfide
as acceptor
GO: 4748 6241 RRM2 2 10262695 10271546 8.96E-01 3.35E-01 3.69E-01 2.65E-01
ribonucleoside-diphosphate
reductase activity, thioredoxin
disulfide as acceptor
GO: 10822 8398 PLA2G6 22 38507502 38577836 9.01E-01 2.91E-01 6.64E-01 1.80E-01
positive regulation of
mitochondrion organization
GO: 90200 8398 PLA2G6 22 38507502 38577836 9.01E-01 2.91E-01 6.64E-01 1.80E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 90200 8739 HRK 12 117299027 117319232 9.10E-01 6.48E-01 8.21E-01 4.30E-01
positive regulation of release of
cytochrome c from mitochondria
GO: 10822 8739 HRK 12 117299027 117319232 9.10E-01 6.48E-01 8.21E-01 4.30E-01
positive regulation of
mitochondrion organization
GO: 10822 5599 MAPK8 10 49609687 49643183 9.32E-01 7.42E-01 8.49E-01 7.87E-01
positive regulation of
mitochondrion organization
GO: 4748
5048
4 RRM2B 8 103216729 103251346 9.38E-01 6.29E-01 8.45E-01 6.44E-06
ribonucleoside-diphosphate
reductase activity, thioredoxin
disulfide as acceptor
GO: 16728
5048
4 RRM2B 8 103216729 103251346 9.38E-01 6.29E-01 8.45E-01 6.44E-06
oxidoreductase activity, acting
on CH or CH2 groups, disulfide
as acceptor
GO: 10822
1407
35 DYNLL2 17 56160780 56167618 9.58E-01 8.08E-01 8.19E-01 8.93E-01
positive regulation of
mitochondrion organization
KEGG
3430
5780
4 POLD4 11 67118236 67121067 9.59E-01 6.48E-01 9.21E-01 3.74E-01 KEGG_MISMATCH_REPAIR
GO: 10822
8470
9 MGARP 4 140187317 140201492 9.78E-01 8.81E-01 8.98E-01 1.51E-01
positive regulation of
mitochondrion organization
Supplementary Table 13: Setscreen enrichment p-values for the Pearl et al. (2015) pathways in TRACK-HD,
REGISTRY, the TRACK-HD meta-analysis and GeM
Gene Set
p(TRAC
K)
p(REGI
STRY)
p(META
) p (GeM) Description1 Description2 Description3 Description4
2071015 9.05E-07 4.43E-03 2.93E-11 2.01E-02 Repair_pathway SSR MMR
Mismatch_and_loop_
recognition_factors
2071000 2.43E-06 6.85E-02 1.49E-14 5.15E-04 Repair_pathway SSR MMR
2070000 5.77E-03 4.76E-02 3.32E-07 1.42E-02 Repair_pathway SSR
2071017 1.95E-02 2.44E-02 5.84E-05 8.92E-08 Repair_pathway SSR MMR MutL_homologs
2111513 4.71E-02 2.55E-01 8.12E-01 2.86E-03 Repair_pathway Associated_process TLS DNA_polymerases
2070600 5.02E-02 7.99E-01 1.10E-01 2.92E-01 Repair_pathway SSR NER
2070607 5.18E-02 7.61E-01 3.02E-02 2.26E-01 Repair_pathway SSR NER
TCR_(Transcription_
coupled_repair)
2071104 5.35E-02 3.90E-01 2.07E-02 5.37E-02 Repair_pathway SSR BER
LONG_PATCH-
BER_factors
2022100 6.69E-02 3.19E-02 7.21E-04 7.29E-02 Repair_pathway DSR Alt-NHEJ
1100000 7.52E-02 6.14E-01 1.94E-01 6.13E-01 Associated_process DNA_replication
1080700 8.99E-02 8.35E-01 2.82E-01 4.92E-01 Associated_process Checkpoint_factors S-CC_phase
1051930 1.02E-01 5.68E-01 1.30E-01 7.62E-01 Associated_process Ubiquitin_response
Ubiquitin-
_conjugating_enz
ymes_(E2)
UBL-
conjugating_enzymes
2000000 1.13E-01 2.60E-01 1.03E-03 1.11E-02 Repair_pathway
2070605 1.14E-01 5.00E-01 8.14E-01 4.64E-01 Repair_pathway SSR NER
DNA_polymerase_ep
silon
1030000 1.59E-01 1.90E-01 3.59E-01 2.63E-01 Associated_process
Telomere_maintena
nce
2070606 1.60E-01 9.56E-01 6.55E-01 5.49E-01 Repair_pathway SSR NER
DNA_polymerase_ka
ppa
2071020 1.73E-01 3.14E-01 9.86E-03 7.97E-02 Repair_pathway SSR MMR Other_MMR_factors
1051900 1.97E-01 7.69E-01 1.71E-01 8.19E-01 Associated_process Ubiquitin_response
Ubiquitin-
_conjugating_enz
ymes_(E2)
2071023 2.15E-01 1.73E-01 7.67E-02 5.90E-01 Repair_pathway SSR MMR
RPA_(replication_fac
tor_A)
1081300 2.15E-01 8.71E-01 4.25E-01 6.96E-01 Associated_process Checkpoint_factors
HRAD17(Rad24)-
_RFC_complex
1051208 2.41E-01 2.50E-01 3.12E-01 5.81E-01 Associated_process Ubiquitin_response
Ubiquitin_ligases
_(E3)
single_Ring-
finger_type_E3
1080900 2.50E-01 4.77E-01 9.41E-01 2.74E-01 Associated_process Checkpoint_factors G1-S_checkpoint
2071003 2.58E-01 8.68E-01 3.40E-01 1.57E-01 Repair_pathway SSR MMR
DNA_polymerase_de
lta
1051222 2.87E-01 2.82E-01 1.50E-01 6.61E-01 Associated_process Ubiquitin_response
Ubiquitin_ligases
_(E3) Riddle_syndrome!
1080800 2.87E-01 3.88E-01 7.69E-01 2.52E-01 Associated_process Checkpoint_factors G1-CC_phase
2070603 2.92E-01 8.34E-01 5.37E-01 4.50E-01 Repair_pathway SSR NER
DNA_polymerase_de
lta
2071010 2.92E-01 7.60E-01 6.37E-01 7.12E-01 Repair_pathway SSR MMR
RFC_(replication_fac
tor_C)
1051221 3.18E-01 1.56E-01 1.06E-02 2.79E-01 Associated_process Ubiquitin_response
Ubiquitin_ligases
_(E3)
Other_single_Ring-
_finger_type_E3
1010000 3.23E-01 4.39E-01 3.23E-01 8.30E-01 Associated_process
Chromatin_remodell
ing
1051829 3.28E-01 5.91E-01 5.58E-01 9.17E-01 Associated_process Ubiquitin_response
Ubiquitin-
_activating_enzy
mes_(E1)
UBL-
activating_enzymes
1051800 3.29E-01 5.91E-01 5.58E-01 9.17E-01 Associated_process Ubiquitin_response
Ubiquitin-
_activating_enzy
mes_(E1)
1051927 3.31E-01 7.89E-01 4.15E-01 6.74E-01 Associated_process Ubiquitin_response
Ubiquitin-
_conjugating_enz
ymes_(E2)
Ubiquitin-
conjugating_enzymes
3060000 3.41E-01 1.70E-01 3.61E-01 7.39E-01
Genes_with_probabl
e_DDR_role
Direct_Repair_(not_
in_humans)
1031600 3.86E-01 8.44E-01 5.12E-01 6.69E-01 Associated_process
Telomere_maintena
nce
Alternative_mech
anism
1031616 3.86E-01 8.44E-01 5.12E-01 6.69E-01 Associated_process
Telomere_maintena
nce
Alternative_mech
anism MRN_Complex
2020200 4.09E-01 6.98E-01 5.00E-01 4.77E-01 Repair_pathway DSR
HR_(Homologous
_Recombination)
1052000 4.20E-01 3.11E-01 4.35E-01 8.24E-01 Associated_process Ubiquitin_response
Ubiquitins_and_U
biquitin-
like_proteins
1052028 4.20E-01 3.11E-01 4.35E-01 8.24E-01 Associated_process Ubiquitin_response
Ubiquitins_and_U
biquitin-
like_proteins Ubiquitins
1000000 4.26E-01 4.38E-01 5.76E-01 3.21E-01 Associated_process
1082500 4.29E-01 1.79E-01 5.65E-01 6.91E-01 Associated_process Checkpoint_factors
FPC_(fork_protec
tion_complex)
2111531 4.30E-01 2.91E-01 2.99E-01 7.84E-01 Repair_pathway Associated_process TLS
Y-
family_DNA_polyme
rases
2071018 4.44E-01 2.64E-01 2.34E-01 1.12E-01 Repair_pathway SSR MMR
MutS_homologs_spe
cialized_for_meiosis
2110000 4.48E-01 4.49E-01 5.96E-01 4.80E-02 Repair_pathway Associated_process
2111500 4.48E-01 4.49E-01 5.96E-01 4.80E-02 Repair_pathway Associated_process TLS
2020000 4.71E-01 4.39E-01 8.35E-02 4.20E-02 Repair_pathway DSR
1050500 4.76E-01 8.55E-01 8.56E-01 7.18E-01 Associated_process Ubiquitin_response
Deubiquitinating_
enzyme_(DUB)
1050501 4.76E-01 8.55E-01 8.56E-01 7.18E-01 Associated_process Ubiquitin_response
Deubiquitinating_
enzyme_(DUB)
UBL-
specific_proteases_(U
LPs)
1080000 4.86E-01 4.50E-01 8.20E-01 2.85E-01 Associated_process Checkpoint_factors
2072800 4.97E-01 5.82E-01 7.02E-02 3.98E-02 Repair_pathway SSR Other_SSR_genes
2020400 5.07E-01 7.84E-01 8.18E-01 5.80E-01 Repair_pathway DSR NHEJ
2071100 5.18E-01 1.14E-01 2.76E-01 1.65E-01 Repair_pathway SSR BER
1082600 5.20E-01 5.64E-01 6.17E-01 5.95E-01 Associated_process Checkpoint_factors G2-CC_phase
1090000 5.70E-01 5.67E-01 6.15E-01 6.62E-01 Associated_process p53_pathway
1050000 5.88E-01 3.44E-01 2.17E-01 7.47E-01 Associated_process Ubiquitin_response
2070602 5.93E-01 1.61E-01 3.08E-01 5.35E-01 Repair_pathway SSR NER
GGR_(Global_genom
e_repair)
2020300 6.05E-01 5.24E-01 6.24E-01 8.22E-01 Repair_pathway DSR Other_DSR_genes
2071119 6.09E-01 6.72E-02 9.07E-01 2.64E-01 Repair_pathway SSR BER Other_BER_factors
2071111 6.11E-01 2.27E-01 5.24E-01 9.70E-01 Repair_pathway SSR BER AP_endonucleases
1082700 6.14E-01 6.85E-01 9.25E-01 1.51E-01 Associated_process Checkpoint_factors G2-M_checkpoint
2021400 6.22E-01 4.96E-02 1.45E-01 9.20E-01 Repair_pathway DSR
HR_(Homologous
Recombination)
1051700 6.42E-01 4.61E-01 5.63E-01 1.52E-01 Associated_process Ubiquitin_response
Ubiquitin-
like_proteins_(UB
Ls)
1051725 6.42E-01 4.61E-01 5.63E-01 1.52E-01 Associated_process Ubiquitin_response
Ubiquitin-
like_proteins_(UB
Ls) SUMO
1051200 6.61E-01 7.44E-02 5.58E-02 3.70E-01 Associated_process Ubiquitin_response
Ubiquitin_ligases
_(E3)
1082900 6.63E-01 8.72E-01 8.87E-01 4.58E-01 Associated_process Checkpoint_factors
Rad17-Mec3-
_Ddc1_complex
1082200 6.69E-01 8.04E-02 2.30E-01 2.61E-01 Associated_process Checkpoint_factors
damage_in_S_pha
se
2111514 7.20E-01 5.25E-01 7.10E-01 4.37E-01 Repair_pathway Associated_process TLS epistasis_group
2020100 7.23E-01 5.41E-01 5.70E-01 2.93E-04 Repair_pathway DSR
FA_(Fanconi_ane
mia_pathway)
1040000 7.46E-01 5.93E-01 6.62E-01 3.78E-01 Associated_process
Chromosome_segre
gation
3000000 7.86E-01 6.19E-01 3.00E-01 7.39E-01
Genes_with_probabl
e_DDR_role
2072300 7.97E-01 3.24E-01 8.88E-01 8.75E-01 Repair_pathway SSR Direct_Repair
2072400 8.27E-01 3.89E-03 6.87E-02 2.76E-01 Repair_pathway SSR DNA_replication
2071124 8.39E-01 8.94E-01 8.19E-01 3.16E-01 Repair_pathway SSR BER
SHORT_PATCH-
BER_factors
2071112 9.02E-01 1.67E-01 3.58E-01 5.51E-01 Repair_pathway SSR BER DNA_glycosylases
1051209 9.25E-01 1.38E-02 5.59E-02 7.56E-01 Associated_process Ubiquitin_response
Ubiquitin_ligases
_(E3)
single_Ring-
finger_type_E4
1120000 9.58E-01 6.23E-01 9.97E-01 6.78E-05 Associated_process
Modulation_of_nucl
eotide_pools
1083000 9.62E-01 7.83E-01 9.16E-01 8.57E-01 Associated_process Checkpoint_factors
RAD9-Hus1-
Rad1_complex
Supplementary Table 14: Gene-wide p-values for the most significant genes in the two Pearl et al. pathways showing
significant enrichment in TRACK
Entre
z
Gene
Symb
ol
Ch
r Start End p(TRACK) p(REG) p(META) p(GeM) Pathways
4437 MSH3 5 79950467 80172634 2.94E-08 9.52E-04 8.88E-11 1.98E-02
Repair_pathway/SSR/MMR/Mismatch_and_l
oop_recognition_factors
5425
POLD
2 7 44154279 44163169 7.21E-04 3.12E-01 2.75E-03 5.17E-01 Repair_pathway/SSR/MMR
3978 LIG1 19 48618703 48673560 1.65E-02 8.28E-02 5.35E-04 6.39E-02 Repair_pathway/SSR/MMR
27030 MLH3 14 75480467 75518235 1.69E-02 6.69E-01 1.47E-01 6.39E-03 Repair_pathway/SSR/MMR
5395 PMS2 7 6012870 6048737 2.58E-02 3.66E-01 8.84E-03 1.76E-05 Repair_pathway/SSR/MMR
4439 MSH5 6 31707725 31730455 4.35E-02 8.54E-01 7.73E-01 5.11E-01 Repair_pathway/SSR/MMR
5982 RFC2 7 73645832 73668738 4.80E-02 5.91E-01 2.02E-02 4.44E-01 Repair_pathway/SSR/MMR
6119 RPA3 7 7676575 7758238 6.55E-02 7.22E-01 9.17E-02 4.37E-01 Repair_pathway/SSR/MMR
4292 MLH1 3 37034841 37092337 6.98E-02 3.97E-04 1.28E-04 3.91E-04 Repair_pathway/SSR/MMR
Supplementary Table 15: Summary of missing data in REGISTRY
Variable N
Missing Values
Count Percent
Motor 1744 91 4.96
Verbal Fluency 1145 690 37.6
Stroop Color 1052 783 42.67
Stroop Color 1116 719 39.18
Stroop Word 1104 731 39.84
Stroop Interference 1092 743 40.49
TFC 1758 77 4.2
FAS score 1616 219 11.93
Supplementary Table 16: Parameter estimates of variables in the model used to generate the REGISTRY cross
sectional severity score. Multiple imputation adjusted estimates of statistical significance are given. CPO_1: clinical
probability of onset; CPO_2: single transformation of clinical probability of onset. DF: degrees of freedom.
Parameter Estimates
Parameter gender Estimate Std Error 95% Confidence Limits DF t for H0: P Val
Intercept 2.075589 0.267283 1.55102 2.60016 897.01 7.77 <.0001
cpo_1 -0.9142 0.21009 -1.32638 -0.50201 1191.6 -4.35 <.0001
cpo_2 -7.00283 0.911001 -8.79025 -5.2154 1141.5 -7.69 <.0001
cag -0.01919 0.005133 -0.02927 -0.00912 862.96 -3.74 0.0002
gender F -0.13631 0.042605 -0.21992 -0.05271 1030.1 -3.2 0.0014
gender M 0 0 . . . . .
Supplementary Table 17: Proportion of variance among variables present in TRACK-HD and
REGISTRY which are accounted for by the first PC in the combined analysis.
Factor Pattern
Factor1
sqrtMotRaw -0.91567
SDMT_correct 0.90797
SWR_correct 0.87904
tfc 0.86045
Supplementary Table 18: Effect of removing MSH3 on the Setscreen enrichment p-values for the top 14 GeM pathways
in TRACK-HD, REGISTRY and the TRACK-REGISTRY meta-analysis.
Pathway p(TRACK)
p(TRACKno
MSH3) p(REGISTRY)
p(REGISTRY
noMSH3) p(META)
p(METAn
oMSH3) Description
GO:
32300 3.455E-09 0.04127 0.0008336 0.07162 1.13E-11 0.001024 mismatch repair complex
KEGG
3430 2.794E-07 0.04521 0.04795 0.1471 1.34E-16 0.000107 KEGG_MISMATCH_REPAIR
GO:
30983 6.661E-07 0.1001 0.0004195 0.009264 3.17E-11 0.000274 mismatched DNA binding
GO:
6298 0.000003533 0.2446 0.04589 0.1839 6.54E-09 0.0729 mismatch repair
GO:
32407 0.01818 0.01818 0.1101 0.1101 0.000640 0.000640 MutSalpha complex binding
GO:
32389 0.02249 0.02249 0.04688 0.04688 0.000523 0.000523 MutLalpha complex
GO:
33683 0.08014 0.08014 0.0005874 0.0005874 0.00675 0.00675
nucleotide-excision repair, DNA
incision
GO:
90141 0.3318 0.3318 0.05934 0.05934 0.7872 0.7872
positive regulation of mitochondrial
fission
GO:
1900063 0.4103 0.4103 0.7287 0.7287 0.6926 0.6926 regulation of peroxisome organization
GO:
90200 0.4582 0.4582 0.544 0.544 0.5280 0.5280
positive regulation of release of
cytochrome c from mitochondria
GO:
90140 0.5385 0.5385 0.3316 0.3316 0.8098 0.8098 regulation of mitochondrial fission
GO:
10822 0.621 0.6228 0.6276 0.6276 0.8527 0.8527
positive regulation of mitochondrion
organization
GO:
4748 0.9639 0.9639 0.6974 0.6974 0.9792 0.9792
ribonucleoside-diphosphate reductase
activity, thioredoxin disulfide as
acceptor
GO:
16728 0.9639 0.9639 0.6974 0.6974 0.9792 0.9792
oxidoreductase activity, acting on CH
or CH2 groups, disulfide as acceptor
Supplementary Table 19: Effect of removing MSH3 on the Setscreen enrichment p-values for the Pearl et al. (2015)
pathways in TRACK-HD, REGISTRY and the TRACK-REGISTRY meta-analysis.
Gene
Set
p(TRACK
)
p(TRA
CKnoM
SH3)
p(REGIS
TRY)
p(REGI
STRYn
oMSH3
)
p(MET
A)
p(MET
A
noMSH
3) Description1 Description2 Description3 Description4
2071
015
9.051E-
07 0.3308 0.00443 0.2821
2.93E-
11 0.5436 Repair_pathway SSR MMR
Mismatch_and_l
oop_recognition_
factors
2071
000
0.000002
43
0.0822
5 0.06854 0.2285
1.49E-
14
0.0001
27 Repair_pathway SSR MMR
2070
000 0.005767 0.2506 0.04762 0.1713
3.32E-
07 0.0549 Repair_pathway SSR
2071
017 0.01947
0.0194
7 0.02442
0.0244
2
5.84E-
05
5.84E-
05 Repair_pathway SSR MMR MutL_homologs
2111
513 0.04707
0.0470
7 0.2549 0.2549 0.8123 0.8123 Repair_pathway
Associated_pro
cess TLS
DNA_polymeras
es
2070
600 0.05024
0.0502
4 0.7989 0.7989 0.1098 0.1098 Repair_pathway SSR NER
2070
607 0.05177
0.0517
7 0.7606 0.7606 0.0302 0.0302 Repair_pathway SSR NER
TCR_(Transcript
ion_coupled_rep
air)
2071
104 0.05345
0.0534
5 0.3895 0.3895 0.0207 0.0207 Repair_pathway SSR BER
LONG_PATCH-
BER_factors
2022
100 0.0669 0.0669 0.03188
0.0318
8
0.0007
2
0.0007
2 Repair_pathway DSR Alt-NHEJ
1100
000 0.07519
0.0751
9 0.6138 0.6138 0.1939 0.1939 Associated_process
DNA_replicatio
n
1080
700 0.08987
0.0898
7 0.8346 0.8346 0.2817 0.2817 Associated_process
Checkpoint_fact
ors S-CC_phase
1051
930 0.1015 0.1015 0.5677 0.5677 0.1303 0.1303 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
_conjugating_e
nzymes_(E2)
UBL-
conjugating_enzy
mes
2000
000 0.1126 0.4184 0.2602 0.3906 0.0010 0.2586 Repair_pathway
2070
605 0.1144 0.1144 0.4998 0.4998 0.8140 0.8140 Repair_pathway SSR NER
DNA_polymeras
e_epsilon
1030
000 0.1588 0.1588 0.1897 0.1897 0.3588 0.3588 Associated_process
Telomere_maint
enance
2070
606 0.1596 0.1596 0.9556 0.9556 0.6550 0.6550 Repair_pathway SSR NER
DNA_polymeras
e_kappa
2071
020 0.1726 0.1726 0.3142 0.3142 0.0099 0.0099 Repair_pathway SSR MMR
Other_MMR_fac
tors
1051
900 0.1973 0.1973 0.7689 0.7689 0.1711 0.1711 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
_conjugating_e
nzymes_(E2)
2071
023 0.2149 0.2149 0.1725 0.1725 0.0767 0.0767 Repair_pathway SSR MMR
RPA_(replication
_factor_A)
1081
300 0.215 0.215 0.8705 0.8705 0.4249 0.4249 Associated_process
Checkpoint_fact
ors
HRAD17(Rad2
4)-
_RFC_complex
1051
208 0.2409 0.2409 0.25 0.25 0.3120 0.3120 Associated_process
Ubiquitin_respo
nse
Ubiquitin_ligas
es_(E3)
single_Ring-
finger_type_E3
1080
900 0.2499 0.2499 0.4774 0.4774 0.9412 0.9412 Associated_process
Checkpoint_fact
ors
G1-
S_checkpoint
2071
003 0.258 0.258 0.8678 0.8678 0.3397 0.3397 Repair_pathway SSR MMR
DNA_polymeras
e_delta
1051
222 0.2873 0.2873 0.2823 0.2823 0.1495 0.1495 Associated_process
Ubiquitin_respo
nse
Ubiquitin_ligas
es_(E3)
Riddle_syndrome
!
1080
800 0.2874 0.2874 0.3878 0.3878 0.7688 0.7688 Associated_process
Checkpoint_fact
ors G1-CC_phase
2070
603 0.292 0.292 0.8344 0.8344 0.5370 0.5370 Repair_pathway SSR NER
DNA_polymeras
e_delta
2071
010 0.2921 0.2921 0.7597 0.7597 0.6366 0.6366 Repair_pathway SSR MMR
RFC_(replication
_factor_C)
1051
221 0.3184 0.3184 0.1559 0.1559 0.0106 0.0106 Associated_process
Ubiquitin_respo
nse
Ubiquitin_ligas
es_(E3)
Other_single_Rin
g-
_finger_type_E3
1010
000 0.3225 0.3225 0.4385 0.4385 0.3231 0.3231 Associated_process
Chromatin_rem
odelling
1051
829 0.3284 0.3284 0.5913 0.5913 0.5578 0.5578 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
_activating_enz
ymes_(E1)
UBL-
activating_enzym
es
1051
800 0.329 0.329 0.5913 0.5913 0.5578 0.5578 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
_activating_enz
ymes_(E1)
1051
927 0.3313 0.3313 0.7885 0.7885 0.4152 0.4152 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
_conjugating_e
nzymes_(E2)
Ubiquitin-
conjugating_enzy
mes
3060
000 0.3405 0.3405 0.1703 0.1703 0.3608 0.3608
Genes_with_probable_
DDR_role
Direct_Repair_(
not_in_humans)
1031
600 0.3856 0.3856 0.8438 0.8438 0.5119 0.5119 Associated_process
Telomere_maint
enance
Alternative_me
chanism
1031
616 0.3856 0.3856 0.8438 0.8438 0.5119 0.5119 Associated_process
Telomere_maint
enance
Alternative_me
chanism MRN_Complex
2020
200 0.4086 0.4086 0.6981 0.6981 0.5004 0.5004 Repair_pathway DSR
HR_(Homologo
us_Recombinati
on)
1052
000 0.42 0.42 0.3114 0.3114 0.4350 0.4350 Associated_process
Ubiquitin_respo
nse
Ubiquitins_and
_Ubiquitin-
like_proteins
1052
028 0.42 0.42 0.3114 0.3114 0.4350 0.4350 Associated_process
Ubiquitin_respo
nse
Ubiquitins_and
_Ubiquitin-
like_proteins Ubiquitins
1000
000 0.426 0.426 0.4378 0.4378 0.5759 0.5759 Associated_process
1082
500 0.4288 0.4288 0.1787 0.1787 0.5650 0.5650 Associated_process
Checkpoint_fact
ors
FPC_(fork_prot
ection_complex
)
2111
531 0.43 0.43 0.2914 0.2914 0.2994 0.2994 Repair_pathway
Associated_pro
cess TLS
Y-
family_DNA_pol
ymerases
2071
018 0.4438 0.4438 0.2644 0.2644 0.2335 0.2335 Repair_pathway SSR MMR
MutS_homologs
_specialized_for_
meiosis
2110
000 0.4479 0.4479 0.4485 0.4485 0.5960 0.5960 Repair_pathway
Associated_pro
cess
2111
500 0.4479 0.4479 0.4485 0.4485 0.5960 0.5960 Repair_pathway
Associated_pro
cess TLS
2020
000 0.471 0.471 0.4388 0.4388 0.0835 0.0835 Repair_pathway DSR
1050
500 0.4757 0.4757 0.8548 0.8548 0.8561 0.8561 Associated_process
Ubiquitin_respo
nse
Deubiquitinatin
g_enzyme_(DU
B)
1050
501 0.4757 0.4757 0.8548 0.8548 0.8561 0.8561 Associated_process
Ubiquitin_respo
nse
Deubiquitinatin
g_enzyme_(DU
B)
UBL-
specific_protease
s_(ULPs)
1080
000 0.4863 0.4863 0.4497 0.4497 0.8204 0.8204 Associated_process
Checkpoint_fact
ors
2072
800 0.4971 0.4971 0.5818 0.5818 0.0702 0.0702 Repair_pathway SSR
Other_SSR_gen
es
2020
400 0.5069 0.5069 0.7838 0.7838 0.8179 0.8179 Repair_pathway DSR NHEJ
2071
100 0.5175 0.5175 0.1144 0.1144 0.2760 0.2760 Repair_pathway SSR BER
1082
600 0.5196 0.5196 0.5642 0.5642 0.6168 0.6168 Associated_process
Checkpoint_fact
ors G2-CC_phase
1090
000 0.5699 0.5699 0.567 0.567 0.6151 0.6151 Associated_process p53_pathway
1050
000 0.5879 0.5879 0.3435 0.3435 0.2168 0.2168 Associated_process
Ubiquitin_respo
nse
2070
602 0.593 0.593 0.1607 0.1607 0.3081 0.3081 Repair_pathway SSR NER
GGR_(Global_ge
nome_repair)
2020
300 0.6054 0.6054 0.5235 0.5235 0.6240 0.6240 Repair_pathway DSR
Other_DSR_ge
nes
2071
119 0.6093 0.6093 0.06716
0.0671
6 0.9067 0.9067 Repair_pathway SSR BER
Other_BER_fact
ors
2071
111 0.6105 0.6105 0.2266 0.2266 0.5242 0.5242 Repair_pathway SSR BER
AP_endonucleas
es
1082
700 0.6144 0.6144 0.6852 0.6852 0.9253 0.9253 Associated_process
Checkpoint_fact
ors
G2-
M_checkpoint
2021
400 0.6216 0.6216 0.04964
0.0496
4 0.1448 0.1448 Repair_pathway DSR
HR_(Homologo
usRecombinatio
n)
1051
700 0.642 0.642 0.461 0.461 0.5626 0.5626 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
like_proteins_(
UBLs)
1051
725 0.642 0.642 0.461 0.461 0.5626 0.5626 Associated_process
Ubiquitin_respo
nse
Ubiquitin-
like_proteins_(
UBLs) SUMO
1051
200 0.6607 0.6607 0.07437
0.0743
7 0.0558 0.0558 Associated_process
Ubiquitin_respo
nse
Ubiquitin_ligas
es_(E3)
1082
900 0.6626 0.6626 0.8717 0.8717 0.8865 0.8865 Associated_process
Checkpoint_fact
ors
Rad17-Mec3-
_Ddc1_complex
1082
200 0.6692 0.6692 0.08041
0.0804
1 0.2304 0.2304 Associated_process
Checkpoint_fact
ors
damage_in_S_p
hase
2111
514 0.7197 0.7197 0.5245 0.5245 0.7104 0.7104 Repair_pathway
Associated_pro
cess TLS epistasis_group
2020
100 0.7228 0.7228 0.5406 0.5406 0.5703 0.5703 Repair_pathway DSR
FA_(Fanconi_a
nemia_pathway
)
1040
000 0.7462 0.7462 0.5933 0.5933 0.6618 0.6618 Associated_process
Chromosome_s
egregation
3000
000 0.7855 0.7855 0.6186 0.6186 0.3003 0.3003
Genes_with_probable_
DDR_role
2072
300 0.7965 0.7965 0.3243 0.3243 0.8883 0.8883 Repair_pathway SSR Direct_Repair
2072
400 0.8269 0.8269 0.00389
0.0038
91 0.0687 0.0687 Repair_pathway SSR
DNA_replicatio
n
2071
124 0.8385 0.8385 0.894 0.894 0.8192 0.8192 Repair_pathway SSR BER
SHORT_PATCH
-BER_factors
2071
112 0.9015 0.9015 0.1669 0.1669 0.3575 0.3575 Repair_pathway SSR BER
DNA_glycosylas
es
1051
209 0.9247 0.9247 0.01381
0.0138
1 0.0559 0.0559 Associated_process
Ubiquitin_respo
nse
Ubiquitin_ligas
es_(E3)
single_Ring-
finger_type_E4
1120
000 0.9579 0.9579 0.6229 0.6229 0.9969 0.9969 Associated_process
Modulation_of_
nucleotide_pool
s
1083
000 0.9619 0.9619 0.7832 0.7832 0.9161 0.9161 Associated_process
Checkpoint_fact
ors
RAD9-Hus1-
Rad1_complex
FIGURES 
Identification of genetic variants 
associated with Huntington’s 
disease progression: a genome-
wide association study
Davina J Hensman Moss*, MBBS, Antonio F. Pardiñas*, PhD, Prof Douglas 
Langbehn, PhD, Kitty Lo, PhD, Prof Blair R. Leavitt, MD,CM, Prof Raymund 
Roos, MD, Prof Alexandra Durr, MD, Prof Simon Mead, PhD, the REGISTRY 
investigators and the TRACK-HD investigators, Prof Peter Holmans, PhD, Prof 
Lesley Jones§, PhD, Prof Sarah J Tabrizi§, PhD  
* These authors contributed equally to this work
§ These authors contributed equally to this work




